Aminoquinazoline derivatives as P2X3 inhibitors

By designing aminoquinazoline derivative compounds as P2X3 receptor antagonists, the problem of the lack of selective compounds in the prior art has been solved, achieving effective treatment of respiratory diseases such as chronic cough while maintaining the protection of taste function.

CN116601149BActive Publication Date: 2026-11-10CHIESI FARMACEUTICI SPA
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202180079588.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-11-27
Filing Date
2021-11-26
Publication Date
2026-11-10
Estimated Expiration
2041-11-26

AI Technical Summary

Technical Problem

There is a lack of novel aminoquinazoline compounds in the current technology that selectively act on P2X3 receptors for the treatment of respiratory disorders such as chronic cough.

Method used

A series of aminoquinazoline derivative compounds have been developed and designed with specific structures to act as antagonists of the P2X3 receptor for the treatment of respiratory diseases.

Benefits of technology

These compounds effectively inhibit P2X3 receptors, reducing symptoms such as chronic cough, while avoiding adverse effects on taste function, demonstrating selective antagonism of P2X3 receptors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0004554865930000051
    Figure GDA0004554865930000051
  • Figure GDA0004554865930000111
    Figure GDA0004554865930000111
  • Figure GDA0004554865930000131
    Figure GDA0004554865930000131
Patent Text Reader

Abstract

This invention relates to compounds of formula I that inhibit P2X purine receptor 3; more specifically, it relates to compounds as aminoquinazoline derivatives, methods for preparing such compounds, pharmaceutical compositions containing them, and their therapeutic uses. The compounds of this invention can be used to treat many disorders associated with the P2X3 receptor mechanism, such as respiratory diseases, including cough, asthma, idiopathic pulmonary fibrosis (IPF), and chronic obstructive pulmonary disease (COPD).
Need to check novelty before this filing date? Find Prior Art

Description

Invention Field

[0001] This invention relates to compounds that inhibit P2X purine receptor 3 (hereinafter referred to as P2X3 inhibitors); specifically, this invention relates to compounds as aminoquinazoline derivatives, methods for preparing such compounds, pharmaceutical compositions containing them, and their therapeutic uses.

[0002] The compounds of the present invention can be used in the treatment of many disorders associated with the P2X3 receptor mechanism, such as respiratory diseases, including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Background of the Invention

[0004] P2X receptors are cell surface ion channels activated by extracellular adenosine triphosphate (ATP). The P2X receptor family consists of trimer assemblies of seven distinct subunit isoforms (P2X1-7), which assemble into homomeric and heteromeric channels. All subunits share a common topology containing intracellular terminals, two transmembrane helices forming the ion channel, and a large extracellular domain containing the ATP-binding site. Homomeric P2X1, P2X2, P2X3, P2X4, P2X5, and P2X7 channels, and heteromeric P2X7 channels... 2 / 3 and P2X 1 / 5 The channels have been fully characterized following heterologous expression. P2X receptors are abundantly distributed and functional responses have been observed in neurons, glial cells, epithelium, endothelium, bone, muscle, and hematopoietic tissues. In smooth muscle, P2X receptors respond to ATP released from sympathetic motor nerves (e.g., during ejaculation). In sensory nerves, they are involved in the initiation of afferent signals in several viscera (e.g., bladder, intestine) and play a key role in sensing tissue damage and inflammatory stimuli. Paracrine effects of ATP signaling via P2X receptors may be present in the neurohypophysis, ductal glands, airway epithelium, kidney, bone, and hematopoietic tissues. (RA. North: Molecular Physiology of P2X Receptors; Physiol Rev, Vol. 82, October 2002). All P2X receptors are non-selective cation channels permeable to Na+ and Ca+ ions and activated by ATP; however, the pharmacology of receptor subtypes varies with sensitivity to ATP and small molecule antagonists. (K Kaczmarek-Hajek et al.: Molecular and functional properties of P2X receptors-recent progress and persisting challenges; Purinergic Signalling 8:375-417, 2012).

[0005] In humans, the P2X3 receptor has been reported to exist at the mRNA level in the heart and spinal cord, and at the protein level in the DRG, gut (intestinal plexus neurons), bladder (urothelial and subepithelial urothelial tracts), and dental pulp (Garcia-Guzman M et al.: Molecular characterization and pharmacological properties of the human P2X3 purinoceptor: Brain Res Mol Brain Res. 1997; 47(1-2): 59-66).

[0006] The neurophysiological role of P2X3 receptors in airway sensory nerve function is similar to that in mediating somatic nociception (Undem BJ and Nassenstein C: Airway nerves and dyspnea associated with inflammatory airway disease, Respir Physiol Nerobiol 167:36-44, 2009). This similarity has driven the hypothesis that P2X3 receptors are involved in symptoms of airway dysfunction, including cough and bronchial hyperresponsiveness (Ford AP: In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and andafferent sensitization, Purinergic signal 8(suppl 1):3-26, 2012; North RA, Jarvis MF P2X Receptors as Drug Targets; Mol Pharmacol, 83:759-769, 2013). The P2X3 subunit is also colocalized in many neurons, particularly in the DRG, tubercular ganglion, nucleus tractus solitarius, and taste buds (Cheung KK, Burnstock G: Localization of P2X3 receptors and coexpression with P2X2 receptors during rat embryonic neurogenesis. J Comp Neurol 443(4):368-382 2002).

[0007] P2X3 antagonists have been proposed for the treatment of diabetic neuropathic pain (Guo J et al.: Contributions of purinergic P2X3 receptors within the midbrain periaqueductalgray to diabetes-induced neuropathic pain, J Physiol Sci Jan; 65(1):99-1042015).

[0008] P2X3 and P2X 2 / 3 Channels play an important role in the development of arthritic hyperalgesia in arthritic joints (Teixeira JM et al.: P2X3 and P2X). 2 / 3 Receptors Play a Crucial Role in Articular HyperalgesiaDevelopment Through Inflammatory Mechanisms in the Knee Joint ExperimentalSynovitis, Mol Neurobiol Oct; 54(8):6174-6186, 2017).

[0009] P2X3 is also a potential target for the therapeutic treatment of bladder pain. It has also been proposed as an analgesic target for treating ureteral colic and facilitating the passage of ureteral stones (Canda AE et al.: Physiology and pharmacology of the human ureter: basis for current and future treatments, Urol Int. 78(4):289-98, 2007).

[0010] P2X3 overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients, and P2X3 has been identified as a potential therapeutic target (Maynard JP et al.: P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients Oncotarget Dec 1; 6(38):41162-79, 2015).

[0011] It has been proposed that P2X3 antagonists can improve the recovery of erectile function (Li CL et al.: Effects of intracavernous injection of P2X3 and NK1 receptor antagonists one rectiledysfunction induced by spinal cord transection in rats, Andrologia. Feb; 47(1):25-9, 2015).

[0012] ATP enhanced citrate-induced and histamine-induced cough in preclinical models, an effect that could be attenuated by a P2X3 selective antagonist (Kamei J and Takahashi Y: Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflexsensitivity in guinea pigs, Oct 10; 547(1-3):160-4, 2006). In humans, local delivery of ATP elicited cough and bronchospasm (Basoglu OK et al.: Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma, Chest. Oct; 128(4):1905-9, 2005).

[0013] Ford and Undem first recognized the therapeutic potential of P2X3 antagonists for the treatment of chronic cough (Ford AP, Undem BJ: The therapeutic promise of ATP antagonism at P2X3 receptors inrespiratory and urological disorders, Front Cell Neurosci, Dec 19; 7:267, 2013). P2X3 is expressed by airway afferent nerves and mediates the hypersensitivity of the cough reflex, which is significantly reduced by oral administration of the P2X3 antagonist AF-219 (Abdulqawi et al.: P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study, Lancet 385, 1198-205, 2015).

[0014] ATP is a key neurotransmitter in the taste system, primarily transmitted via P2X. 2 / 3 Heterogeneous multimer receptors play a role. Therefore, disruption of taste function may be an unintentional result of therapeutic trials for pain, chronic cough, and other conditions using purinergic P2X3 antagonists (Vandenbeuch A et al.: Role of the ectonucleotidase NTPDase2 in tastebud function, Proc Natl Acad Sci USA, Sep 3; 110(36):14789-94, 2013. Bo X et al.: Localization of ATP-gated P2X2 and P2X3 receptor immunoreactive nerves in rattaste buds, Neuroreport, 10(5):1107-11, 1999).

[0015] It has already been described in the literature as P2X3 and / or P2X 2 / 3 Various compounds that act as inhibitors.

[0016] WO2017058645 (Afferent Pharmaceuticals INC) discloses diaminopyrimidine P2X3 / P2X 2 / 3The antagonist is used to treat disorders including cough, chronic cough, and cough urges, including coughs associated with respiratory illnesses or disorders, by administering an effective amount of the disclosed compound. However, aminoquinazoline derivatives are not disclosed.

[0017] WO2017011729 (Patara Pharma LLC) discloses cromoglycine or a pharmaceutically acceptable salt thereof and P2X3 and / or P2X. 2 / 3 Receptor antagonists are used as antitussives to treat lung diseases and conditions.

[0018] WO2016091776 (Evotec AG) discloses 1,3-thiazol-2-yl-substituted benzamide compounds that inhibit the P2X3 receptor and pharmaceutical compositions containing such compounds, as well as the use of the compounds for the treatment of several disorders, including respiratory diseases.

[0019] WO2016088838 (Shionogi) discloses novel P2X3 and / or P2X... 2 / 3 Purine derivative compounds with receptor antagonistic effects.

[0020] WO2016084922 (Shionogi) discloses novel P2X3 and / or P2X 2 / 3 Triazine derivative compounds with receptor antagonistic effects.

[0021] WO2008123963 (Renovis) relates to fused heterocyclic compounds of the tetrahydropyrido[4,3-d]pyrimidine class and pharmaceutical compositions comprising such compounds. Methods for the prevention and / or treatment of several disorders, such as neurodegenerative disorders, pain, asthma, and autoimmune disorders, are also provided.

[0022] WO2008130481 (Renovis) discloses 2-cyanophenyl fused heterocyclic compounds of the tetrahydropyridino[4,3-d]pyrimidine class and pharmaceutical compositions comprising such compounds.

[0023] WO2010033168 (Renovis) discloses a series of benzamides substituted with phenyl or pyridyl groups, which are claimed to be useful for treating diseases related to P2X purinergic receptors, and more specifically involving P2X3 receptors and / or P2X. 2 / 3 Receptor antagonists. However, aminoquinazoline derivatives are not disclosed.

[0024] WO2009110985 (Renovis) relates to phenyl- and pyridyl-substituted benzamide compounds and pharmaceutical compositions comprising such compounds but not thiazole-substituted benzamides, such that the compounds are different from those of the present invention.

[0025] WO2008000645 (Roche) disclosed P2X3 and / or P2X. 2 / 3 Tetraazole-substituted aryl amide antagonists for receptors can be used to treat urogenital, pain, gastrointestinal and respiratory diseases, symptoms and disorders.

[0026] Despite the aforementioned prior art, there remains a need for novel aminoquinazoline compounds in many therapeutic areas for treating diseases associated with the P2X3 receptor, such as respiratory diseases in particular, preferably with selective action on the P2X3 receptor.

[0027] It is noteworthy that the prior art does not describe or imply the aminoquinazoline derivative compounds of general formula (I) of the present invention, which represent the solution required above. Invention Overview

[0029] This invention relates to compounds of formula (I).

[0030]

[0031] in

[0032] X is selected from S, SO2, SO, or O;

[0033] Z is selected from the group consisting of heteroaryl and aryl groups, wherein any one of such heteroaryl and aryl groups may optionally be substituted by one or more groups selected from (C1-C3) alkyl-, halogen and (C1-C6) haloalkyl-.

[0034] R1 is H or (C1-C4) alkyl;

[0035] R2 is a heteroaryl (C1-C4)alkyl-, wherein either such alkyl or heteroaryl may optionally be substituted by one or more groups selected from (C1-C3)alkyl, (C1-C6) haloalkyl and halogen;

[0036] R is selected from (C1-C6)alkyl-, (C1-C6)alkyl-CN, (C1-C6) haloalkyl, and -NR. A R B (C3-C8)heterocyclic alkyl-(C1-C6)alkyl-, (C3-C8)heterocyclic alkyl-, (C3-C8)heteroaryl-(C1-C6)alkyl-, (C3-C8)cycloalkyl-(C1-C6)alkyl-, (C3-C8)cycloalkyl-, R AO-(C1-C6)alkyl-O-(C1-C6)alkyl-, R A NH-C(O)-(C1-C4)alkyl-, R A R B NC(O)-(C1-C4)alkyl-, R A The group consisting of OC(O)(C1-C6) alkyl groups.

[0037] In which any one of such heterocyclic alkyl groups is unsubstituted or is selected from OH, -C(O)R A -C(O)OR A Substitution with (C1-C6) haloalkyl, -NH-C(O)R1 and oxo groups;

[0038] Any one of such cycloalkyl groups is selected from one or more of -C(O)OR A Substitution with (C1-C6) haloalkyl groups,

[0039] Any of such heteroaryl groups may optionally be substituted by one or more groups selected from (C1-C6)alkyl-, -OH and (C3-C6)cycloalkyl-;

[0040] R A and R B Each time it appears, it is independently H or selected from the following groups: (C1-C6)alkyl-, (C1-C6)haloalkyl-, -OR1, -SO2R C and (C3-C6) cycloalkyl groups, wherein such cycloalkyl groups may optionally be substituted with one or more -C(O)OR1 groups, or alternatively...

[0041] R A and R B They can form 5- or 6-membered saturated heterocyclic monocyclic systems together with the nitrogen atoms to which they are attached, which optionally contain additional heteroatoms as nitrogen or oxygen, which may optionally be substituted by one or more groups selected from halogens and -OR1.

[0042] R C It is aryl;

[0043] The premise is that R is (C1-C6) alkyl- or unsubstituted (C3-C8) heterocyclic alkyl- only when X is S or SO.

[0044] In a second aspect, the present invention relates to pharmaceutical compositions comprising a compound of formula (I) alone or in combination with one or more pharmaceutically acceptable carriers or excipients, or a pharmaceutically acceptable salt thereof.

[0045] In a third aspect, the present invention provides a compound of formula (I) which is used as a drug.

[0046] In another aspect, the present invention provides the use of compounds of formula (I) in the treatment of any disease involving the P2X3 receptor.

[0047] In another aspect, the present invention relates to compounds of formula (I) for the prevention and / or treatment of respiratory diseases, including cough, subacute or chronic cough, refractory cough, idiopathic chronic cough, postviral cough, iatrogenic cough, asthma, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cough associated with respiratory diseases such as COPD, asthma, and bronchospasm. Invention Details

[0049] Unless otherwise provided, the term (I) means, in its sense, a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate.

[0050] As used herein, the term “pharmaceutically acceptable salt” refers to a derivative of a compound of formula (I), wherein the parent compound is suitably modified by converting any free acid or basic group (if present) into the corresponding addition salt using any base or acid conventionally expected to be pharmaceutically acceptable.

[0051] Suitable examples of the salt may therefore include inorganic or organic acid addition salts of basic residues such as amino groups, and inorganic or organic basic addition salts of acidic residues such as carboxyl groups.

[0052] As used herein, the term "halogen" or "halogen atom" includes fluorine, chlorine, bromine, and iodine atoms, preferably chlorine or fluorine.

[0053] The term "(C)" x -C y "alkyl" refers to a straight-chain or branched alkyl group having x to y carbon atoms, where x and y are integers. Therefore, when x is 1 and y is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and n-hexyl.

[0054] As used herein, the term "(C)" x -C y "alkylene", where x and y are integers, refers to C atoms with a total of two unsaturated valences. x -C y Alkyl groups, such as dimethyl groups.

[0055] The expression "(C) x -C y ")haloalkyl", where x and y are integers, referring to "C" as defined above.x -C y An alkyl group, wherein one or more hydrogen atoms are replaced by one or more halogen atoms, which may be the same or different.

[0056] Therefore, the "(C) x -C y Examples of "halogenated alkyl" can include halogenated, polyhalogenated, and perhalogenated alkyl groups in which all hydrogen atoms are replaced by halogen atoms, such as trifluoromethyl or difluoromethyl, trifluoroethyl.

[0057] Similarly, the terms "(C1-C6)hydroxyalkyl" or "(C1-C6)aminoalkyl" refer to the "(C1-C6)alkyl" as defined above, wherein one or more hydrogen atoms are replaced by one or more hydroxyl (OH) or amino groups, respectively. Examples include hydroxymethyl, aminomethyl, dimethylaminopropyl, etc.

[0058] In this specification, unless otherwise provided, aminoalkyl groups include those containing one or more amino groups (-NR). A R B Aminoalkyl groups are substituted alkyl groups (i.e., "(C1-C6)alkyl"). Therefore, examples of aminoalkyl groups are monoaminoalkyl groups, such as R... A R B N-(C1-C6)alkyl.

[0059] The term "(C)" x -C y "Cycloalkyl", where x and y are integers, refers to a saturated cyclic hydrocarbon group containing a specified number of cyclic carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0060] The term "aryl" refers to a monocyclic carbocyclic system with six ring atoms, wherein the ring is aromatic. Examples of suitable aryl monocyclic systems include, for example, phenyl.

[0061] The term "heteroaryl" refers to a monocyclic or bicyclic aromatic group containing one or more heteroatoms selected from S, N, and O, and includes groups having two such monocyclic rings or one such monocyclic ring and a monocyclic aryl ring fused together by a common bond. Suitable examples of 5- or 6-membered heteroaryls are: thienyl, furanyl, pyrroleyl, imidazolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridinyl, pyrazinyl, tetrazolyl, and triazinyl.

[0062] The term "heterocyclic group" or "heterocyclic" refers to a saturated monocyclic, bicyclic, or tricyclic nonaromatic group containing one or more heteroatoms selected from S, N, and O. In the case of bicyclic heterocyclic systems, fused, helical, and bridged bicyclic systems are included within the scope of the term.

[0063] The term "(C)" x -C y "Heterocyclic alkyl", where x and y are integers, refers to a saturated or partially unsaturated monocyclic (C) alkyl group. x -C y A cycloalkyl group, wherein at least one ring carbon atom is substituted by at least one heteroatom (e.g., N, S, or O) or may have an oxo (=O) substituent. The heterocycloalkyl group (i.e., a radical or group of heterocyclic residues) may further optionally be substituted at available positions in the ring, i.e., on a carbon atom or on a heteroatom that can be substituted. Substitution on the carbon atom includes spirodisubstituted substitution and substitution on two adjacent carbon atoms, thus forming an additional fused 5- to 6-membered heterocycle in both cases. (C) x -C y Examples of heterocyclic alkyl groups are represented by the following: pyrrolyl, imidazoalkyl, thiazoalkyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, dihydro- or tetrahydro-pyridinyl, tetrahydrothiopheneyl, azahexacyclobutyl, oxacyclobutyl, tetrahydropyranyl, pyranyl, 2H- or 4H-pyranyl, dihydro- or tetrahydrofuranyl, dihydroisoxazoyl, pyrrolidine-2-one-yl, dihydropyrrolyl, etc.

[0064] Specific examples of the heterocyclic groups are tetrahydrothiophene 1,1-dioxide, 3,3-difluoropyrrolidinyl, 1-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, and 4-morpholinyl.

[0065] The terms "aryloxy" and "aryl(C1-C6)alkoxy," and similarly "heteroaryloxy" and "heteroaryl(C1-C6)alkoxy," refer to aryl or heteroaryl groups linked by oxygen bridges, as well as chained aryl-alkoxy or heteroaryl-alkoxy groups. Examples of such groups are phenoxy, benzyloxy, and pyridyloxy.

[0066] The term "aryl (C1-C6) alkyl" refers to an aryl ring attached to a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as phenylmethyl (i.e., benzyl), phenylethyl, or phenylpropyl.

[0067] Terminology (C) z -C k Heterocyclic alkyl-(C x -C y Alkyl, where z and k are integers, refers to a heterocycle attached to a straight-chain or branched alkyl group having x to y carbon atoms.

[0068] Similarly, the term "heteroaryl (C)" x -C y alkyl or aryl (C x -Cy "alkyl" refers to a heteroaryl or aryl ring that is attached to a straight-chain or branched alkyl group having x to y carbon atoms.

[0069] The term "cyclic system" refers to a cyclic system that can be saturated, partially unsaturated, or unsaturated monocyclic, bicyclic, or polycyclic, such as aryl, (C3-C4) rings. 10 (C3-C6) cycloalkyl, (C3-C6) heterocycloalkyl or heteroaryl.

[0070] The terms “group,” “residue,” “segment,” or “substituent” are synonymous and are intended to indicate a functional group or segment of a molecule that can be attached to a bond or other segment or molecule. Thus, by way of example, “heterocyclic group” herein refers to a monocyclic or bicyclic saturated or partially saturated heterocyclic moiety (group, residue), preferably a 4- to 11-membered monocyclic group, wherein at least one additional ring carbon atom in the heterocyclic group is optionally replaced by at least one additional heteroatom independently selected from N, S, or O and / or may have an oxo (=O) substituent, the heterocyclic group further optionally including spirodisubstituted and substitutions on two adjacent or adjacent atoms, forming an additional 5- to 6-membered ring or a saturated, partially saturated, or aromatic ring of heterocyclic form. Examples of such heterocyclic groups are 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, etc.

[0071] A dash ("-") not between two letters or symbols is intended to indicate the connection point of a substituent. When represented graphically, the connection point in a cyclic functional group is indicated by a dot ("·") located in one of the available ring atoms, where the functional group can be attached to a bond or other segment of the molecule.

[0072] As an alternative to other common representations such as (=O), the oxo group is represented by (O). Therefore, for the purposes of the general formula, the carbonyl group is represented herein as -C(O)-. Generally, the group enclosed in brackets is a side group not included in the chain, and brackets are used when deemed appropriate to help eliminate ambiguity in linear chemical formulas; for example, the sulfonyl group -SO2- can also be represented as -S(O)2- to eliminate ambiguity, for example, regarding the sulfinic acid group -S(O)O-.

[0073] Whenever a basic amino or quaternary ammonium group is present in a compound of Formula I, a physiologically acceptable anion may be present, selected from chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, p-toluenesulfonate, dihydroxynaphthylate, and naphthalenedisulfonate. Similarly, in the presence of an acidic group such as a COOH group, a corresponding physiologically acceptable cation salt may also be present, including alkali metal or alkaline earth metal ions.

[0074] It will be obvious that when the compound of formula (I) contains one or more stereocenters, it can exist as an optical stereoisomer.

[0075] When compounds according to the invention have at least one stereocenter, they may exist as enantiomers accordingly. When compounds according to the invention have two or more stereocenters, they may additionally exist as diastereomers. All such single enantiomers, diastereomers, and mixtures thereof in any proportion are included within the scope of the invention. The absolute configuration (R) or (S) of the carbon with the stereocenter is specified based on the Cahn-Ingold-Prelog nomenclature rule, which is based on the priority of the functional groups.

[0076] The present invention further relates to corresponding deuterated derivatives of compounds of formula (I).

[0077] All preferred groups or embodiments described above and below for compounds of Formula I can be combined with each other and are subject to necessary modifications.

[0078] As shown above, the present invention relates to a series of compounds represented by general formula (I) as described in detail below, which impart antagonistic properties relative to receptor P2X3.

[0079] Unlike similar compounds in the prior art, the compounds of formula (I) of the present invention are capable of acting as antagonists P2X3 in a substantial and effective manner, which is particularly understood by those skilled in the art when seeking suitable and effective compounds for the treatment of respiratory diseases, especially chronic cough.

[0080] As shown in the experimental section, the compounds of formula (I) exhibit the activities shown in Table 2, where the half-maximal inhibitory concentration (pIC50) against the receptor is reported for each compound. 50 The effect indicated by )

[0081] As another advantage, it has been unexpectedly found that compounds of formula (I) primarily and selectively inhibit P2X3 receptors, and that these compounds can be used to treat respiratory diseases while avoiding adverse effects such as loss of taste response. Indeed, as can be understood from Table 3, the P2X receptor... 2 / 3 In comparison, the compound of formula (I) exhibits greater activity relative to the receptor P2X3.

[0082] Therefore, in one aspect, the present invention relates to compounds of general formula (I) as P2X3 antagonists.

[0083]

[0084] in

[0085] X is selected from S, SO2, SO, or O;

[0086] Z is selected from the group consisting of heteroaryl and aryl groups, wherein any one of such heteroaryl and aryl groups may optionally be substituted by one or more groups selected from (C1-C3) alkyl-, halogen and (C1-C6) haloalkyl-.

[0087] R1 is H or (C1-C4) alkyl;

[0088] R2 is a heteroaryl (C1-C4)alkyl-, wherein either such alkyl or heteroaryl may optionally be substituted by one or more groups selected from (C1-C3)alkyl, (C1-C6) haloalkyl and halogen;

[0089] R is selected from (C1-C6)alkyl-, (C1-C6)alkyl-CN, (C1-C6) haloalkyl, and -NR. A R B (C3-C8)heterocyclic alkyl-(C1-C6)alkyl-, (C3-C8)heterocyclic alkyl-, (C3-C8)heteroaryl-(C1-C6)alkyl-, (C3-C8)cycloalkyl-(C1-C6)alkyl-, (C3-C8)cycloalkyl-, R A O-(C1-C6)alkyl-O-(C1-C6)alkyl-, R A NH-C(O)-(C1-C4)alkyl-, R A R B NC(O)-(C1-C4)alkyl-, R A The group consisting of OC(O)(C1-C6) alkyl groups.

[0090] In which any one of such heterocyclic alkyl groups is unsubstituted or is selected from OH, -C(O)R A -C(O)OR A Substitution with (C1-C6) haloalkyl, -NH-C(O)R1 and oxo groups;

[0091] Any one of such cycloalkyl groups is selected from one or more of -C(O)OR A Substitution with (C1-C6) haloalkyl groups,

[0092] Any of such heteroaryl groups may optionally be substituted by one or more groups selected from (C1-C6)alkyl-, -OH and (C3-C6)cycloalkyl-;

[0093] R A and R BEach time it appears, it is independently H or selected from the following groups: (C1-C6)alkyl-, (C1-C6)haloalkyl-, -OR1, -SO2R C and (C3-C6) cycloalkyl groups, wherein such cycloalkyl groups may optionally be substituted with one or more -C(O)OR1 groups, or alternatively...

[0094] R A and R B They can form 5- or 6-membered saturated heterocyclic monocyclic systems together with the nitrogen atoms to which they are attached, which optionally contain additional heteroatoms as nitrogen or oxygen, which may optionally be substituted by one or more groups selected from halogens and -OR1.

[0095] R C It is aryl;

[0096] The premise is that R is (C1-C6) alkyl- or unsubstituted (C3-C8) heterocyclic alkyl- only when X is S or SO.

[0097] In a preferred embodiment, Z is selected from the group consisting of heteroaryl and aryl groups, wherein the heteroaryl group is selected from pyridine and pyrimidine.

[0098] In another preferred embodiment, R2 is a heteroaryl (C1-C4)alkyl-, wherein the heteroaryl group is selected from the group consisting of pyridazine, thiadiazole, pyrimidine and oxadiazole.

[0099] In a preferred embodiment, the present invention relates to at least one of the compounds listed in Table 1 below and a pharmaceutically acceptable salt thereof.

[0100] Table 1 lists the preferred compounds of formula (I).

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113] In a preferred embodiment, the present invention relates to compounds of formula (I),

[0114]

[0115] in

[0116] X is selected from S or SO;

[0117] Z is an aryl group, wherein such an aryl group may optionally be substituted by one or more groups selected from (C1-C3) alkyl-, halogen and (C1-C6) haloalkyl-;

[0118] R1 is H or (C1-C4) alkyl;

[0119] R2 is a heteroaryl (C1-C4)alkyl-, wherein either such alkyl or heteroaryl may optionally be substituted by one or more groups selected from (C1-C3)alkyl, (C1-C6) haloalkyl and halogen;

[0120] R is selected from the group consisting of (C1-C6)alkyl- and (C3-C8) heterocyclic alkyl-.

[0121] In a preferred embodiment, the present invention relates to compounds of formula (I), wherein X is O, which is represented by formula Ia.

[0122]

[0123] in

[0124] Z is selected from the group consisting of heteroaryl and aryl groups, wherein any one of such heteroaryl and aryl groups may optionally be substituted by one or more groups selected from (C1-C3) alkyl-, halogen and (C1-C6) haloalkyl-.

[0125] R1 is H or (C1-C4) alkyl;

[0126] R2 is a heteroaryl (C1-C4)alkyl-, wherein either such alkyl or heteroaryl may optionally be substituted by one or more groups selected from (C1-C3)alkyl, (C1-C6) haloalkyl and halogen;

[0127] R is selected from (C1-C6)alkyl-, (C1-C6)alkyl-CN, (C1-C6) haloalkyl, and -NR. A R B(C3-C8)heterocyclic alkyl-(C1-C6)alkyl-, (C3-C8)heterocyclic alkyl-, (C3-C8)heteroaryl-(C1-C6)alkyl-, (C3-C8)cycloalkyl-(C1-C6)alkyl-, (C3-C8)cycloalkyl-, R A O-(C1-C6)alkyl-O-(C1-C6)alkyl-, R A NH-C(O)-(C1-C4)alkyl-, R A R B NC(O)-(C1-C4)alkyl-, R A The group consisting of OC(O)(C1-C6) alkyl groups.

[0128] Any one of such heterocyclic alkyl groups is selected from one or more groups selected from -OH, -C(O)R A -C(O)OR A Substitution with (C1-C6) haloalkyl, -NH-C(O)R1 and oxo groups;

[0129] Any one of such cycloalkyl groups is selected from one or more of -C(O)OR A Substitution with (C1-C6) haloalkyl groups,

[0130] Any of such heteroaryl groups may optionally be substituted by one or more groups selected from (C1-C6)alkyl-, -OH and (C3-C6)cycloalkyl-;

[0131] R A and R B Each time it appears, it is independently H or selected from the following groups: (C1-C6)alkyl-, (C1-C6)haloalkyl-, -OR1, -SO2R C and (C3-C6) cycloalkyl groups, wherein such cycloalkyl groups may optionally be substituted with one or more -C(O)OR1 groups;

[0132] R C It is an aryl group.

[0133] In a preferred embodiment, the present invention relates to compounds of formula (I), wherein X is SO2, which is represented by formula Ib.

[0134]

[0135] in

[0136] Z is an aryl group, wherein any of such aryl groups may optionally be substituted by one or more groups selected from (C1-C3) alkyl-, halogen and (C1-C6) haloalkyl-.

[0137] R1 is H or (C1-C4) alkyl;

[0138] R2 is a heteroaryl (C1-C4)alkyl-, wherein either such alkyl or heteroaryl may optionally be substituted by one or more groups selected from (C1-C3)alkyl, (C1-C6) haloalkyl and halogen;

[0139] R is -NR A R B ;

[0140] R A and R B Each time it appears, it is independently H or (C1-C6)alkyl-, or alternatively

[0141] R A and R B They can form 5- or 6-membered saturated heterocyclic monocyclic systems together with the nitrogen atoms to which they are attached, which optionally contain additional heteroatoms as nitrogen or oxygen, which may optionally be substituted by one or more groups selected from halogens or -OR1.

[0142] Compounds of formula (I), including all of the compounds or at least one of the compounds listed above, can generally be prepared using generally known methods according to the procedures detailed in the schemes shown below.

[0143] Option 1

[0144]

[0145] In one embodiment of the invention, compound (Ia) can be prepared from compound (II) according to scheme 1. Compound (II) is prepared according to the method described in J. Med Chem., 2015, 58(8), 3548-3571.

[0146] Compound (III) can be prepared from compound (II) by deoxyamination mediated by a suitable amine (reagent 1) via a coupling agent such as PyBOP.

[0147] Compound (VI) can be prepared from compound (III) by metal-catalyzed cross-coupling reactions such as Stille or Suzuki or similar reactions as described in “Transition Metals for Organic Synthesis”, 2nd edition, 1, 2004, with suitable reagents such as (reagent 2).

[0148] Alternatively, compound (V) can be prepared from compound (III) via a metal-catalyzed Miyaura borylation reaction.

[0149] Compound (VI) can be prepared from compound (V) by metal-catalyzed cross-coupling reactions such as Stille, Suzuki or similar reactions as described in “Transition Metals for Organic Synthesis”, 2nd edition, 1, 2004, with a suitable organohalogen compound such as (reagent 3).

[0150] In another embodiment, compound (IV) is prepared from compound (II) by a metal-catalyzed cross-coupling reaction such as Stille, Suzuki or similar reaction as described in “TransitionMetals for Organic Synthesis”, 2nd edition, 1, 2004, with a suitable organometallic reagent such as (reagent 2).

[0151] Compound (VI) can be prepared from compound (IV) by a suitable amine-mediated deoxyamination reaction using a reagent such as PyBOP or a similar reagent (Reagent 1).

[0152] Compound (VII) can be prepared from compound (VI) by means of a dealkylation reaction mediated by a strong Lewis acid such as BBr3 or the like.

[0153] Compound (Ia) is prepared by alkylation of compound (VII) with a suitable alkylating agent (reagent 4) such as alkyl chloride, alkyl bromide, alkyl iodide, alkyl methanesulfonate, alkyl toluenesulfonate or the like.

[0154] Alternatively, compound (Ia) can be prepared from compound (VII) and a suitable alcohol (reagent 5) via a Mitsunobu-like reaction mediated by, for example, DEAD / PPh3, DIAD / PPh3 or CMT.

[0155] Some compounds (Ia) may contain protected hydroxyl or amino groups, which are then removed using known methods.

[0156] Option 2

[0157]

[0158] In one embodiment of the invention, compound (Ia) can be prepared from compound (VIII) according to scheme 2.

[0159] Compound (IX) can be prepared by aromatic substitution of compound (VIII) and a suitable alcohol (reagent 5) in the presence of a suitable base such as, for example, potassium carbonate (K2CO3).

[0160] Compound (X) can be prepared from compound (IX) by hydrogenation in the presence of a suitable catalyst, such as palladium / carbon.

[0161] Compound (XI) can be prepared from compound (X) by halogenation with suitable reagents such as bromine, NBS, NIS, iodine, iodonium or the like.

[0162] Compound (XII) can be prepared from compound (XI) by metal-catalyzed cross-coupling reactions such as Stille, Suzuki or similar reactions with a suitable organometallic reagent (reagent 2) such as, for example, an organoboron compound.

[0163] Compound (XIII) can be prepared from compound (XII) by ester hydrolysis mediated by a suitable base such as, for example, lithium hydroxide (LiOH).

[0164] Compound (XIV) can be prepared from compound (XIII) via a quinazoline ring construction reaction using suitable reagents such as formamide or the like.

[0165] Compound (XV) can be prepared from compound (XIV) by a deoxyhalogenation reaction mediated by a reagent such as, for example, phosphorus oxychloride.

[0166] Compound (Ia) can be prepared from compound (XV) by reacting a suitable amine (reagent 1) in the presence of a base such as, for example, TEA or DIPEA.

[0167] Some compounds (Ia) may contain protected hydroxyl or amino groups, which are then removed using known methods.

[0168] Option 2a

[0169]

[0170] In another embodiment of the invention, compound (Ia) may also be prepared from compound (XI) according to scheme 2a.

[0171] Compound (XIIa) can be prepared from compound (XI) by ester hydrolysis mediated by a suitable base such as, for example, lithium hydroxide (LiOH).

[0172] Compound (XIIIa) can be prepared from compound (XIIa) via a quinazoline ring construction reaction using suitable reagents such as formamide or the like.

[0173] Compound (XIV) can be prepared from compound (XIIIa) by metal-catalyzed cross-coupling reactions such as Stille, Suzuki or similar reactions with suitable organometallic reagents (reagent 2) such as organoboron compounds, for example.

[0174] Compound (Ia) can be prepared from compound (XIV) as described in Scheme 2.

[0175] Option 3

[0176]

[0177] In another embodiment of the invention, compound (Ib) can be prepared from compound (XVI) according to scheme 3.

[0178] Compound (XVII) can be prepared from compound (XVI) by amination in the presence of a suitable amine (reagent 6).

[0179] Compound (XVIII) can be prepared from compound (XVII) by halogenation with suitable reagents such as bromine, NBS, NIS, iodine, iodonium or the like.

[0180] Compound (XIX) can be prepared by a quinazoline ring construction reaction of compound (XVIII) with a suitable reagent such as formamide or the like.

[0181] Compound (XX) can be prepared from compound (XIX) by metal-catalyzed cross-coupling reactions such as Stille, Suzuki or similar reactions using a suitable organometallic reagent (reagent 2), such as organoboron compounds.

[0182] Compound (Ib) can be prepared from compound (XX) by amination reaction in the presence of a suitable amine (reagent 1).

[0183] Some compounds (Ib) may contain protected hydroxyl or amino groups, which are then removed using known methods.

[0184] Option 4

[0185]

[0186] In another embodiment of the invention, compounds (Ic) and (Id) can be prepared from compound (XXI) according to scheme 4.

[0187] Compound (XXII) can be prepared from compound (XXI) by metal-catalyzed thiolation with a suitable organosulfur reagent (reagent 7).

[0188] Compound (Ic) can be prepared from compound (XXII) by deoxyamination mediated by a suitable amine (reagent 1) via a coupling agent such as PyBOP.

[0189] Alternatively, compound (XXIII) can be prepared from compound (XXI) by deoxyamination mediated by a suitable amine (reagent 1) with a coupling agent such as PyBOP.

[0190] Compound (Ic) can be prepared from compound (XXIII) by metal-catalyzed thiolation with a suitable organosulfur reagent (reagent 7).

[0191] Compound (Id) can be prepared from compound (Ic) by oxidation with a reagent such as, for example, mCPBA.

[0192] Alternatively, compound (XXIIa) can be prepared from compound (XXII) by oxidation with a reagent such as mCPBA.

[0193] Compound (Id) can be prepared from compound (XXIIa) by deoxyamination mediated by a suitable amine (reagent 1) via a coupling agent such as PyBOP.

[0194] Compound (Id) can be prepared from compound (XXIIa) by deoxyamination mediated by a suitable amine (reagent 1) via a coupling agent such as PyBOP.

[0195] Some compounds (Ic) may contain protected hydroxyl or amino groups, which are then removed using known methods.

[0196] It has been unexpectedly found that the compounds of the present invention effectively inhibit P2X3 receptors, and that the compounds can be used to treat respiratory diseases.

[0197] In one embodiment, it has been unexpectedly found that the representative compound of formula (I) of the present invention effectively and selectively inhibits the P2X3 receptor, and said compound can be used to treat respiratory diseases while avoiding adverse effects such as loss of taste response.

[0198] In a preferred embodiment, the compound of formula (I) is a selective P2X3 antagonist, wherein the selectivity of the selective P2X3 antagonist for antagonizing the P2X3 homopolymer receptor is relative to P2X. 2 / 3 It has at least 10 times the antagonistic effect of heteroadrenergic receptors.

[0199] In another preferred embodiment, the selectivity of the selective P2X3 antagonist for the antagonistic effect of the P2X3 homopolymer receptor is relative to P2X. 2 / 3 It has at least 30 times the antagonistic effect of heteropolymer receptors.

[0200] In another preferred embodiment, the selectivity of the selective P2X3 antagonist for the antagonistic effect of the P2X3 homopolymer receptor is relative to P2X. 2 / 3 It has at least 50 times the antagonistic effect of heteropolymer receptors.

[0201] The present invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof mixed with one or more pharmaceutically acceptable carriers or excipients, said compound of formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with one or more other active ingredients.

[0202] In one aspect, the present invention relates to compounds of formula (I) according to the invention, which are used as pharmaceuticals.

[0203] In another aspect, the present invention relates to the use of compounds of formula (I) of the present invention or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating disorders related to the P2X3 receptor mechanism, preferably for treating respiratory diseases.

[0204] Preferably, the present invention relates to compounds of formula (I) for the prevention and / or treatment of respiratory diseases, preferably cough, subacute or chronic cough, refractory cough, idiopathic chronic cough, postviral cough, iatrogenic cough, asthma, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cough associated with respiratory diseases such as COPD, asthma, and bronchospasm.

[0205] More preferably, the present invention relates to compounds of formula (I) for the prevention and / or treatment of chronic cough and cough associated with respiratory diseases such as COPD, asthma and bronchospasm.

[0206] The present invention also provides a method for preventing and / or treating disorders related to the P2X3 receptor mechanism, the method comprising administering a therapeutically effective amount of the compound of the present invention to a patient in need of such treatment.

[0207] In particular, the present invention relates to methods for preventing and / or treating disorders, wherein the disorder is cough, subacute or chronic cough, refractory cough, idiopathic chronic cough, postviral cough, iatrogenic cough, asthma, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cough associated with respiratory diseases such as COPD, asthma, and bronchospasm, wherein the method comprises administering an appropriate amount of a compound of formula (I) to a patient in need.

[0208] In another preferred embodiment, the obstacle is chronic cough.

[0209] The treatment method of the present invention comprises administering to a patient in need a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. As used herein, a “safe and effective amount” for a compound of formula (I) or a pharmaceutically acceptable salt thereof, or other pharmaceutically active agent, means an amount sufficient to treat the patient’s condition but low enough to avoid serious side effects, and which can still be routinely determined by a person skilled in the art. A compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered once or according to a dosing regimen in which multiple doses are administered at different time intervals within a given period of time. Typical daily doses may vary depending on the specific route of administration chosen.

[0210] The present invention also provides pharmaceutical compositions of compounds of formula (I) mixed with one or more pharmaceutically acceptable carriers or excipients, such as those described in Remington's Pharmaceutical Sciences Handbook, XVII, Mack Pub., NY, USA.

[0211] The compounds of the present invention and their pharmaceutical compositions can be administered according to the patient's needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally, and by infusion), and by inhalation.

[0212] Preferably, the compounds of the present invention can be administered orally or by inhalation. More preferably, the compounds of the present invention can be administered orally.

[0213] Various solid oral dosage forms can be used to administer the compounds of the present invention, including solid forms such as tablets, soft capsules, capsules, pouches, granules, lozenges, and bulk powders. The compounds of the present invention can be administered alone or in combination with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, and starch), and known excipients (including suspending agents, solubilizers, buffers, binders, disintegrants, preservatives, colorants, flavoring agents, lubricants, etc.). Time-release capsules, tablets, and gels are also advantageous in administering the compounds of the present invention.

[0214] Preferably, the compound of the present invention is administered in tablet form.

[0215] Various liquid oral dosage forms can also be used to administer the compounds of the present invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms may also contain suitable known inert diluents such as water and suitable known excipients such as preservatives, wetting agents, sweeteners, flavoring agents, and agents for emulsifying and / or suspending the compounds of the present invention. The compounds of the present invention can be administered intravenously, for example, in the form of isotonic sterile solutions.

[0216] For the treatment of respiratory diseases, the compounds according to the invention are preferably administered by inhalation.

[0217] Inhalable formulations include inhalable powders, metered aerosols containing propellants, or inhalable formulations without propellants.

[0218] For administration as a dry powder, single-dose or multi-dose inhalers known in the art can be used. In this case, the powder can be filled in gelatin, plastic, or other capsules, cartridges, or blister packs, or filled in a reservoir.

[0219] Chemically inert diluents or carriers, such as lactose or any other additives suitable for improving the breathable fraction, can be added to the powdered compounds of the present invention.

[0220] Inhalation aerosols containing propellant gases such as hydrofluorocarbons may contain the compounds of the present invention in solution or dispersion form. Propellant-driven formulations may also contain other components such as solubilizers, stabilizers, and optionally other excipients.

[0221] Propellant-free inhalable formulations containing the compounds of the present invention may be in the form of solutions or suspensions in aqueous, alcoholic, or hydroalcoholic media, and may be delivered by jet or ultrasonic sprayers known in the art or by soft mist sprayers.

[0222] Preferably, the compound of the present invention is administered orally.

[0223] The compounds of the present invention can be administered as a single active agent or in combination with other pharmaceutical active ingredients.

[0224] Preferably, the compounds of the present invention can be combined with therapeutic agents or active ingredients that can be used to treat diseases related to or mediated by the P2X3 receptor.

[0225] The dosage of the compounds of the present invention depends on a variety of factors, including, in particular, the specific disease to be treated, the severity of symptoms, and the route of administration.

[0226] The present invention also relates to a device comprising a pharmaceutical composition comprising a compound of formula (I) according to the invention, in the form of a single-dose or multi-dose dry powder inhaler or metered-dose inhaler.

[0227] The following examples illustrate various aspects of the invention described in this application. These examples are not intended to limit the invention in any way.

[0228] The embodiments and test experiments described herein are for illustrative purposes only, and the invention is not limited to the given embodiments.

[0229] Preparation and Examples of Intermediates

[0230] Use Dotmatics software to generate chemical names. In some cases, use the generally accepted names of commercially available reagents instead of the names generated by Dotmatics software.

[0231] All reagents not described in the experimental section are commercially available, or are known compounds, or can be formed by those skilled in the art from known compounds using known methods.

[0232] (R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethylamine HCl and (R)-1-(6-methylpyridazin-3-yl)ethyl-1-amine HCl were prepared according to the procedure described in WO2016 / 091776.

[0233] Abbreviation - Meaning

[0234] Et2O: Diethyl ether;

[0235] Et3N: Triethylamine;

[0236] TEA: Triethylamine;

[0237] DCC: N,N'-Dicyclohexylcarbodiimide;

[0238] PyBOP: (benzotriazol-1-yloxy)tripyrrolidinylphosphonium hexafluorophosphate;

[0239] DMF: Dimethylformamide;

[0240] EtOAc: Ethyl acetate;

[0241] RT: Room temperature;

[0242] THF: Tetrahydrofuran;

[0243] DCM: Dichloromethane;

[0244] MeOH: Methanol;

[0245] EtOH: Ethanol;

[0246] TFA: Trifluoroacetic acid;

[0247] LC-MS: Liquid Chromatography / Mass Spectrometry;

[0248] HPLC: High-performance liquid chromatography;

[0249] MPLC: Medium-pressure liquid chromatography;

[0250] SFC: Supercritical Fluid Chromatography;

[0251] dppf: 1,1'-bis(diphenylphosphino)ferrocene;

[0252] DIEA or DIPEA: N,N-diisopropylethylamine;

[0253] MeCN: Acetonitrile;

[0254] MTBE: tert-butyl methyl ether;

[0255] TBDMSCl: tert-butyl(chloro)dimethylsilane;

[0256] DMSO: Dimethyl sulfoxide;

[0257] Boc2O: ditert-butyl dicarbonate;

[0258] UPLC: Ultra-high performance liquid chromatography.

[0259] mCPBA: m-chloroperbenzoic acid

[0260] General experimental details and methods

[0261] Analytical methods

[0262] Liquid chromatography-mass spectrometry

[0263] Method 1

[0264] UPLC-MS was performed on a Waters Acquity I-Class with a Waters diode array detector coupled to a Waters SQD2 single quadrupole mass spectrometer using a Waters HSS C18 column (1.8 μm, 100 × 2.1 mm). The column was initially held for 1.2 min at 5% acetonitrile / water (with 0.1% formic acid in each mobile phase), followed by a linear gradient of 5–100% over 3.5 min, and then held at 100% for 1.5 min (F = 0.5 mL / min).

[0265] Method 2

[0266] UPLC-MS was performed on a Waters Acquity I-Class with a Waters diode array detector coupled to a Waters SQD2 single quadrupole mass spectrometer using a Waters BEH Shield RP18 column (1.7 μm, 100 × 2.1 mm). The column was initially held for 1.2 min at 5% acetonitrile / water (with 10 mM ammonium bicarbonate in each mobile phase), followed by a linear gradient of 5–100% over 3.5 min, and then held at 100% for 1.5 min (F = 0.5 mL / min).

[0267] Method 3

[0268] UPLC-MS was performed on a Waters DAD+Waters SQD2 single quadrupole UPLC-MS mass spectrometer using an AcquityUPLC BEH Shield RP18 1.7µm 100×2.1mm (Plus guard cartridge) column. The column was maintained at column temperature and initially held for 0.4 min at 5% acetonitrile / water (with 10 mM ammonium bicarbonate in each mobile phase), followed by a linear gradient of 5–95% over 6.4 min, and then held at 95% for 1.2 min (F = 0.4 mL / min).

[0269] Method 4

[0270] UPLC-MS was performed on a Waters DAD+Waters SQD2 single quadrupole UPLC-MS mass spectrometer using an AcquityUPLC BEH Shield RP18 1.7µm 100×2.1mm (Plus guard column). The column was maintained at column temperature and initially held for 0.4 min at 5% acetonitrile (far UV grade) with 0.1% (V / V) formic acid / water (high purity via PureLab Option unit) with 0.1% formic acid. This was followed by a linear gradient of 5–95% over 6.4 min and then held at 95% for 1.2 min (F = 0.4 mL / min).

[0271] Method 5

[0272] An Aquity UPLC-QDa mass spectrometer with a C18 reversed-phase column (50 × 2.1 mm Acquity CSH, with a particle size of 1.7 μm) was used, maintained at 40 °C, and eluted with A: 95 / 5 water / acetonitrile + 0.05% formic acid; B: 95 / 5 acetonitrile / water + 0.05% formic acid.

[0273] gradient:

[0274]

[0275]

[0276] Detection - MS, UV PDA

[0277] MS ionization method - electrospray (positive / negative ion).

[0278] Method 5A

[0279] An Aquity UPLC-QDa mass spectrometer with a C18 reversed-phase column (50 × 2.1 mm Acquity CSH, with a particle size of 1.7 μm) was used, maintained at 40 °C, and eluted with A: 95 / 5 water / acetonitrile + 0.05% formic acid; B: 95 / 5 acetonitrile / water + 0.05% formic acid.

[0280] gradient:

[0281]

[0282] Detection - MS, UV PDA

[0283] MS ionization method - electrospray (positive / negative ion).

[0284] Method 6

[0285] The Aquity UPLC-QDa mass spectrometer, equipped with a C18 reversed-phase column (50×2.1mm Acquity BEH, with a particle size of 1.7μm), was maintained at 40°C and eluted with A: 95 / 5 water / acetonitrile + 0.05% concentrated ammonia; and B: 95 / 5 acetonitrile / water + 0.05% concentrated ammonia.

[0286] gradient:

[0287]

[0288] Detection - MS, UV PDA

[0289] MS ionization method - electrospray (positive / negative ionization)

[0290] Method 7

[0291] Equipped with 2.6 μm XB-C18 (4.6 × 50 mm), 110A DAD detector / Thermo Scientific MSQ Pluse Dionex UHPLC Ultimate 3000, maintained at 25 °C, eluted with A: 0.1% v / v formic acid in aqueous solution and B: 0.1% v / v formic acid in acetonitrile solution.

[0292] gradient:

[0293] Time [min] Flow rate [ml / min] Mobile phase A [%) Mobile phase B [%] 0.0 1.0 95 5 1.0 1.0 95 5 4.75 1.0 20 80 5.25 1.0 20 80 6.0 1.0 95 5 7.0 1.0 95 5

[0294] Detection - MS, UV PDA

[0295] MS ionization method - electrospray (positive / negative ionization)

[0296] NMR

[0297] Unless otherwise specified, the solvent was used at approximately room temperature at 300 or 400 MHz using a Bruker or Varian instrument. 1 1H nuclear magnetic resonance (NMR) spectroscopy. In all cases, the NMR data are consistent with the proposed structure. Characteristic chemical shifts (δ) are given in parts per million using conventional abbreviations for the main peaks: for example, s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet; dt, doublett; m, multiplet; br, broad peak.

[0298] Preparative reversed-phase HPLC conditions

[0299] Preparative HPLC purification was performed by reversed-phase HPLC using a Waters Fractionlynx preparative HPLC system (2525 pump, 2996 / 2998 UV / VIS detector, 2767 liquid processor) or an equivalent HPLC system such as the Gilson Trilution UV directional system. The Waters 2767 liquid processor was used as the autosampler and fraction collector. Columns used for preparative purification of the compounds were 10 μm 19 × 150 mm Waters Sunfire OBD Phenomenex Luna Phenyl Hexyl or Waters Xbridge Phenyl, or Waters CSH Phenyl Hexyl, 19 × 150, 5 μm columns. An appropriate focused gradient was selected based on the acetonitrile and methanol solvent system under acidic or basic conditions. The modifiers used under acidic / basic conditions were formic acid or trifluoroacetic acid (0.1% V / V) and ammonium bicarbonate (10 mM), respectively. Purification was controlled by Waters Fractionlynx software via monitoring in the 210–400 nm range, with a collection threshold triggered at 260 nm. The presence of the target molecular ion was observed under API conditions when using Fractionlynx. The collected fractions were analyzed by LCMS (Waters Acquity system with Waters SQD).

[0300] Chiral supercritical fluid chromatography (SFC) separation scheme

[0301] Diastereomeric separation of compounds was achieved by supercritical fluid chromatography (SFC) using a Waters Thar Prep100 preparative SFC system (P200 CO2 pump, 2545 modifier pump, 2998 UV / VIS detector, and 2767 liquid processor with stacked injection module). The Waters 2767 liquid processor was used as the autosampler and fraction collector. Appropriate isocratic methods were selected based on the solvent system of methanol, ethanol, or isopropanol under unmodified or alkaline conditions. The standard SFC method used was modifier, CO2, 100 mL / min, 120 bar back pressure, and a column temperature of 40 °C. The modifier used under alkaline conditions was diethylamine (0.1% v / v). The modifier used under acidic conditions was formic acid (0.1% v / v) or trifluoroacetic acid (0.1% v / v). SFC purification was controlled by monitoring in the 210–400 nm range using Waters Fractionlynx software and triggered at the collection threshold (typically 260 nm). The collected fractions were analyzed by SFC (Waters / Thar SFC system with Waters SQD). The fraction containing the desired product was concentrated by vacuum centrifugation.

[0302] Supercritical fluid chromatography-mass spectrometry analysis conditions

[0303] Method 8

[0304] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-3 column, with 15% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0305] Method 9

[0306] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-3 column, with 20% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0307] Method 10

[0308] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 55% ethanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0309] Method 11

[0310] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 20% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0311] Method 12

[0312] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 30% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0313] Method 13

[0314] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 50% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0315] Method 14

[0316] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 25% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0317] Method 15

[0318] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 15% ethanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0319] Method 16

[0320] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 25% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0321] Method 17

[0322] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 35% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0323] Method 18

[0324] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 55% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0325] Method 19

[0326] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column with 15% methanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0327] Method 20

[0328] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 20% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0329] Method 21

[0330] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Cellulose-C column, with 15% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0331] Method 22

[0332] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Cellulose-C column, with 15% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0333] Method 23

[0334] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Cellulose-C column, with 25% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0335] Method 24

[0336] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Cellulose-SC column, with 55% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0337] Method 25

[0338] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-3 column, with 10% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0339] Method 26

[0340] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-3 column, with 25% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0341] Method 27

[0342] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-3 column, with 30% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0343] Method 28

[0344] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 40% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0345] Method 29

[0346] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 40% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0347] Method 30

[0348] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 50% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0349] Method 31

[0350] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 55% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0351] Method 32

[0352] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a Lux Cellulose-4 column, with 55% methanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0353] Method 33

[0354] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 20% ethanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0355] Method 34

[0356] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 30% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0357] Method 35

[0358] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 30% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0359] Method 36

[0360] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 40% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0361] Method 37

[0362] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Amylose-C column, with 55% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0363] Method 38

[0364] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Cellulose-C column, with 20% methanol / CO2 (containing 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature isocratic operation.

[0365] Method 39

[0366] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Cellulose-SC column, with 35% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0367] Method 40

[0368] SFC-MS was performed on a Waters / Thar SFC system with Waters SQD, using a YMC Cellulose-SC column, with 45% isopropanol / CO2 (with 0.1% diethylamine), at 5 mL / min, 120 bar back pressure, and 40 °C column temperature.

[0369] Intermediate 1

[0370] 2-Amino-5-bromo-3-methoxybenzoic acid hydrobromide

[0371]

[0372] At 0 °C, a solution of bromine (6.0 g, 1.9 mL, 37.70 mmol) in chloroform (15 mL) was added dropwise over a period of one hour to a suspension of 2-amino-3-methoxybenzoic acid (6.0 g, 35.90 mmol) in chloroform (180 mL). The reaction was stirred for another five hours and allowed to slowly rise to room temperature. The solvent was removed under vacuum, and the residue was ground with diethyl ether. The reaction was filtered to give the title compound (11.3 g, 96%) as a beige solid.

[0373] LCMS (Method 4): [MH+] = 247, at 4.07 min.

[0374] Intermediate 2

[0375] 6-Bromo-8-methoxyquinazoline-4-ol

[0376]

[0377] A solution of 2-amino-5-bromo-3-methoxybenzoic acid hydrobromide (intermediate 1) (10.0 g, 30.60 mmol) in formamide (40 mL) was heated to 165 °C for 18 hours. After returning to room temperature, the reaction mixture was diluted with water (100 mL) and poured into ice water (400 mL) and filtered. The solid was washed with water (200 mL) and diethyl ether (200 mL) to give the title compound (5.9 g, 76%) as a light brown solid.

[0378] LCMS (Method 4): [MH+] = 255, at 3.07 min.

[0379] Intermediate 3

[0380] 6-(4-Fluorophenyl)-8-methoxyquinazoline-4-ol

[0381]

[0382] Nitrogen gas was bubbled through a mixture of 6-bromo-8-methoxyquinazoline-4-ol (intermediate 2) (1.18 g, 4.63 mmol), 4-fluorophenylboronic acid (710 mg, 5.09 mmol), and cesium carbonate (5.73 g, 17.58 mmol) in 1,4-dioxane (30 mL) and water (7.5 mL) for 5 min. Then, a complex of [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride with dichloromethane (190 mg, 0.23 mmol) was added, and the reaction was heated to 110 °C for 5 h. After returning to room temperature, the reaction mixture was diluted with water (20 mL), filtered, and the solid was washed with a 10% methanol solution in diethyl ether, followed by washing with diethyl ether to give the title compound (1.0 g, 80%) as a beige solid.

[0383] LCMS (Method 5): [MH+] = 271.1 at 0.81 min.

[0384] Intermediate 4

[0385] 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine

[0386]

[0387] To a solution of 6-(4-fluorophenyl)-8-methoxyquinazoline-4-ol (intermediate 3) (100 mg, 0.37 mmol) in N,N-dimethylformamide (2 mL), phosphonium hexafluorophosphate (212 mg, 0.41 mmol) and diisopropylethylamine (0.32 mL, 1.85 mmol) were added sequentially. The resulting mixture was heated to 40 °C and stirred for 20 min, then 1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl-1-amine (67 mg, 0.41 mmol) was added and heating was maintained at 40 °C for 18 h. After returning to room temperature, the mixture was diluted with ethyl acetate (50 mL) and water (20 mL). The organic phase was washed with brine (2 × 20 mL), passed through a hydrophobic glass frit, and the solvent was removed under vacuum. The residue was purified by preparative HPLC to give the title compound (43 mg, 31%) as a white solid.

[0388] ¹H NMR (400MHz, DMSO): δ 8.85 (d, J = 6.8Hz, ¹H), 8.49 (s, ¹H), 8.24 (s, ¹H), 7.99 (dd, J = 5.6, 8.6Hz, 2H), 7.61 (s, ¹H), 7.44 (dd, J = 8.8, 8.8Hz, 2H), 5.88–5.82 (m, ¹H), 4.08 (s, 3H), 2.37 (s, 3H), 1.78 (d, J = 7.1Hz, 3H). LCMS (Method 4): [MH+] = 375 at 3.29 min.

[0389] The compounds reported in the table below were synthesized according to the same method described for the preparation of 6-(4-fluorophenyl)-8-methoxy-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)quinazolin-4-amine (intermediate 4).

[0390]

[0391] Intermediate 6

[0392] (R)-6-bromo-8-methoxy-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine

[0393]

[0394] To a solution of 6-bromo-8-methoxyquinazoline-4-ol (intermediate 2) (65 mg, 0.27 mmol) in N,N-dimethylformamide (1.5 mL), phosphonium hexafluorophosphate (139 mg, 0.27 mmol) and diisopropylethylamine (0.2 mL, 0.81 mmol) were added sequentially. The resulting mixture was heated to 60 °C for one hour, followed by the addition of (R)-1-(6-methylpyridazin-3-yl)ethyl-1-amine (65 mg, 0.27 mmol), and heating was maintained at 60 °C for 18 hours. After returning to room temperature, the reaction mixture was concentrated directly onto silica gel and purified by silica gel chromatography by elution with ethyl acetate solution in the range of 0–100% (10% MeOH in ethyl acetate) to give the title compound as a beige solid (100 mg, quantitative yield).

[0395] LCMS (Method 4): [MH+] = 374 at 2.42 min.

[0396] The following intermediates reported in the table below were synthesized according to the same procedure described for the preparation of (R)-6-bromo-8-methoxy-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine (intermediate 6):

[0397]

[0398] Intermediate 9

[0399] 6-(4-fluoro-2-methoxyphenyl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine

[0400]

[0401] To a solution of 6-bromo-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (intermediate 8) (70 mg, 0.19 mmol) in 1,2-dimethoxyethane (3.0 mL), (4-fluoro-2-methoxyphenyl)boronic acid (41 mg, 0.24 mmol), a complex of [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride with dichloromethane (8.2 mg, 0.01 mmol), cesium carbonate (130 mg, 0.40 mmol), and water (0.3 mL) were added. The resulting mixture was heated to 95 °C for 18 h. After returning to room temperature, the reaction was subjected to... Filter. Rinse with ethyl acetate (2 × 20 mL). Filter cake. The combined organic phases were washed with brine (2 × 20 mL), filtered through a hydrophobic glass filter, and the solvent was removed under vacuum. The residue was purified by preparative HPLC to give the title compound (35 mg, 45%) as a grayish-white solid.

[0402] ¹H NMR (400MHz, DMSO): δ 8.92 (dd, J = 5.8, 5.8Hz, ¹H), 8.41 (s, ¹H), 7.91 (d, J = 1.5Hz, ¹H), 7.54–7.46 (m, 3H), 7.37 (d, J = 1.4Hz, 1H), 7.10 (dd, J = 2.4, 11.5Hz, 1H), 6.97–6.91 (m, 1H), 4.99 (d, J = 5.6Hz, 2H), 3.93 (s, 3H), 3.84 (s, 3H), 2.59 (s, 3H). LCMS (Method 3): [MH+] = 406 at 3.97 min.

[0403] The following compounds, reported in the table below, were prepared by adjusting the above procedure from the appropriate intermediates reported in the table.

[0404]

[0405]

[0406] Intermediate 12

[0407] 6-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine

[0408]

[0409] Nitrogen gas was bubbled through a mixture of 6-bromo-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (intermediate 8) (100 mg, 0.28 mmol), bis(neopentyl)diboron (66 mg, 0.29 mmol), a complex of [1,1'-bis(diphenylphosphine)ferrocene]-palladium(II) dichloride with dichloromethane (10 mg, 0.02 mmol), and potassium acetate (54 mg, 0.55 mmol) in 3.0 mL of 1,4-dioxane for 5 min. The mixture was heated to 100 °C for 3 h. After returning to room temperature, the mixture was used as a 1,4-dioxane solution for the next step without further purification.

[0410] Intermediate 13

[0411] Preparation of 8-methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylthiazo-2-yl)quinazolin-4-amine

[0412]

[0413] To the above solution of 6-(5,5-dimethyl-1,3,2-dioxaborane-2-yl)-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (100 mg, 0.28 mmol), an aqueous solution of cesium carbonate (181 mg, 0.56 mmol, 0.4 mL), 2-bromo-5-methylthiazole (64 mg, 0.28 mmol), and tetrakis(triphenylphosphine)palladium(0) (20 mg, 0.02 mmol) were added. The resulting mixture was heated to 95 °C for 16 hours. After returning to room temperature, the mixture was subjected to… The filter cake was filtered and washed with ethyl acetate (2 × 10 mL). The organic phase was washed with a saturated aqueous solution of ammonium chloride (10 mL), passed through a hydrophobic glass frit, and the solvent was removed under vacuum. The residue was purified by preparative HPLC to give the title compound (25 mg, 24%) as a grayish-white solid.

[0414] ¹H NMR (400MHz, DMSO): δ 9.24 (dd, J = 5.7, 5.7Hz, ¹H), 8.43 (s, ¹H), 8.37 (d, J = 1.5Hz, ¹H), 7.75 (d, J = 1.5Hz, ¹H), 7.68 (d, J = 1.1Hz, ¹H), 7.57 (d, J = 8.7Hz, ¹H), 7.50 (d, J = 8.7Hz, ¹H), 5.02 (d, J = 5.8Hz, 2H), 4.00 (s, 3H), 2.60 (s, 3H), 2.50 (s, 3H). LCMS (Method 3): [MH+] = 379 at 3.20 min.

[0415] The following compounds, as reported in the table below, were prepared according to the same procedure described for the preparation of 8-methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylthiazo-2-yl)quinazolin-4-amine (intermediate 13).

[0416]

[0417] Intermediate 15

[0418] 8-Methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)quinazolin-4-amine

[0419]

[0420] Nitrogen gas was bubbled through a mixture of 6-bromo-8-methoxy-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (intermediate 8) (250 mg, 0.69 mmol), bis-(pinacolyl)diboron (194 mg, 0.76 mmol), [1,1'-bis-(diphenylphosphino)-ferrocene]palladium(II) dichloride (25 mg, 0.03 mmol), and potassium acetate (204 mg, 2.08 mmol) in 1,4-dioxane (15.0 mL) for 5 min. The mixture was heated at 90 °C for 18 h. After returning to room temperature, the reaction was passed through... The solvent is removed by filtration and vacuum. The residue is used in the next step without further purification.

[0421] Intermediate 16

[0422] 8-Methoxy-6-(5-methyl-1,3,4-thiadiazol-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine

[0423]

[0424] Nitrogen gas was bubbled through a mixture of 2-bromo-5-methyl-1,3,4-thiadiazole (34 mg, 0.19 mmol), 8-methoxy-N-((6-methylpyridazin-3-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)quinazolin-4-amine (70 mg, 0.17 mmol), potassium carbonate (36 mg, 0.26 mmol), and water (0.5 mL) in 1,4-dioxane (4.0 mL) for 5 min, followed by the addition of tetrakis(triphenylphosphine)palladium(0) (20 mg, 0.02 mmol). The resulting mixture was heated to 95 °C for 16 h. After returning to room temperature, the reaction was passed through... Filter and wash with ethyl acetate (20 mL). Combine the organic phases, pass them through a hydrophobic glass frit, and remove the solvent under vacuum. Purify the residue by preparative HPLC to give the title compound (21.0 mg, 32%) as a grayish-white solid.

[0425] ¹H NMR (400MHz, DMSO): δ 9.31 (dd, J = 5.8, 5.8Hz, ¹H), 8.47 (s, ¹H), 8.44 (d, J = 1.7Hz, ¹H), 7.80 (d, J = 1.4Hz, ¹H), 7.58 (d, J = 8.7Hz, ¹H), 7.51 (d, J = 8.7Hz, ¹H), 5.03 (d, J = 5.8Hz, 2H), 4.03 (s, 3H), 2.84 (s, 3H), 2.60 (s, 3H). LCMS (Method 3): [MH+] = 380 at 2.13 min.

[0426] The following compounds reported in the table below were prepared according to the same procedure described for the preparation of 8-methoxy-6-(5-methyl-1,3,4-thiadiazol-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (intermediate 16):

[0427]

[0428]

[0429] Intermediate 18

[0430] (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)-quinazolin-8-ol

[0431]

[0432] At 0 °C, boron tribromide (0.32 mL, 3.32 mmol) was added dropwise to a solution of 6-(4-fluorophenyl)-8-methoxy-N-[(1R)-1-[2-(trifluoromethyl)-pyrimidin-5-yl]ethyl]quinazolin-4-amine (intermediate 10) (490 mg, 1.11 mmol) in chloroform (8 mL). The reaction was then allowed to rise to room temperature and heated to 65 °C for 18 hours. After returning to room temperature, the reaction was cooled in an ice bath and quenched with methanol (2 mL). The solvent was removed under vacuum. The residue was diluted with ethyl acetate (50 mL) and washed with a saturated aqueous solution of NaHCO3 (50 mL). The aqueous layer was then extracted with ethyl acetate (2 × 20 mL). The organic phases were combined, passed through a hydrophobic glass frit, and the solvent was removed under vacuum to give the title compound (416 mg, 88%) as a gray solid.

[0433] ¹H NMR (400MHz, DMSO): δ 9.18 (s, 2H), 8.65 (d, J = 7.0Hz, 1H), 8.46 (s, 1H), 8.09 (s, 1H), 7.86 (dd, J = 5.5, 8.7Hz, 2H), 7.45 (d, J = 1.3Hz, 1H), 7.37 (dd, J = 8.8, 8.8Hz, 2H), 5.71–5.67 (m, 1H), 1.75 (d, J = 7.0Hz, 3H), OH not observed.

[0434] The following compounds were prepared by adjusting the above procedure starting from the substrates reported in the table.

[0435]

[0436]

[0437] Example 1

[0438] 8-(2,2-Difluoroethoxy)-6-(4-fluorophenyl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine

[0439]

[0440] To a suspension of 6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-ol (100 mg, 0.28 mmol) (intermediate 19) and cesium carbonate (180 mg, 0.55 mmol) in DMF (1.6 mL), 1,1-difluoro-2-iodoethane (0.04 mL, 0.41 mmol) was added, and the reaction was stirred at 70 °C for 2 h. The mixture was concentrated under reduced pressure, and the resulting crude product was purified by rapid chromatography (Biotage Isolera, 30 g C18 column, gradient elution from 0% to 70% of solution A of B. A: water / acetonitrile 95:5 + 0.05% HCOOH, B: acetonitrile / water 95:5 + 0.05% HCOOH) to give the title product as a white solid (14.9 mg, 0.03 mmol, 12.7% yield).

[0441] 1H NMR(400MHz,DMSO-d6)δppm 9.05(br s,1H),8.41(s,1H),8.21-8.25(m,1H),7.88-7.95(m,2H),7.60-7.66(m,1H),7.43-7.54(m,2H),7.34(t,J= 8.88Hz, 2H), 6.49 (dt, J = 1.00Hz, 1H), 4.99 (d, J = 5.48Hz, 2H), 4.58 (td, J = 14.47, 3.73Hz, 2H), 2.55 (s, 3H).

[0442] Example 2

[0443] (R)-8-(2,2-difluoroethoxy)-6-(4-fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine

[0444]

[0445] A suspension of (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-ol (100 mg, 0.23 mmol) (intermediate 18), cesium carbonate (152 mg, 0.47 mmol) and 1,1-difluoro-2-iodoethane (0.03 mL, 0.35 mmol) in DMF (1.6 mL) was stirred at 70 °C for 2 h.

[0446] The mixture was then cooled and partitioned between DCM (10 mL) and 1 M HCl aqueous solution (10 mL), and the organic phase was separated. The mixture was then concentrated under reduced pressure, and the crude product was purified by RP rapid chromatography (Biotage Isolera, 12 g C18 column, gradient elution from 0 to 100% of solution A of B. A: water / acetonitrile 95:5 + 0.05% HCOOH, B: acetonitrile / water 95:5 + 0.05% HCOOH) to give the title product as a yellow solid (53.5 mg, 0.108 mmol, 46.6% yield).

[0447] 1¹H NMR (600MHz, DMSO-d⁶) δppm 9.16 (s, 2H) 8.66 (d, J = 6.80Hz, 1H) 8.44 (s, 1H) 8.28 (d, J = 1.54Hz, 1H) 7.95 (dd, J = 8.78, 5.45Hz, 2H) 7.65 (d, J = 1.67Hz, 1H) 7.39 (t, J = 8.43Hz, 2H) 6.38-6.65 (m, 1H) 5.67 (quintet, J = 6.99Hz, 1H) 4.60 (td, J = 14.43, 3.72Hz, 2H) 1.73 (d, J = 7.18Hz, 3H).

[0448] LCMS (Method 5): [MH+] = 493.67 at 0.86 min.

[0449] Intermediate 21

[0450] Methyl 3-(2,2-difluoroethoxy)-2-nitrobenzene

[0451]

[0452] A DMF solution of methyl 3-fluoro-2-nitrobenzoate (600 mg, 3.00 mmol) and 2,2-difluoroethanol (544 mg, 6.63 mmol) was added to a 10 mL microwave-safe vial. Potassium carbonate (833 mg, 6.03 mmol) was added to the stirred solution, and the mixture was heated in a microwave reactor to 120 °C for 20 minutes. This procedure was repeated three times, and the combined reaction mixture was cooled to room temperature, poured into water (65 mL), and extracted with diethyl ether (30 mL). The aqueous phase was then extracted with additional diethyl ether (2 × 30 mL). The combined organic layers were dried over magnesium sulfate, filtered, and the solvent was removed under vacuum. The resulting residue was purified by rapid silica gel column chromatography, eluting with a solution of 50% ethyl acetate in cyclohexane, to give the title compound (1876 mg, 81%) as a pale yellow solid.

[0453] ¹H NMR (400MHz, CDCl₃): δ 7.71–7.68 (m, ¹H), 7.55–7.51 (m, ¹H), 7.30–7.26 (m, ¹H), 6.22–5.92 (m, ¹H), 4.34–4.26 (m, 2H), 3.91–3.90 (m, 3H). LCMS (Method 3): [MH⁺] = 262 at 4.17 min.

[0454] Intermediate 22

[0455] Methyl 2-amino-3-(2,2-difluoroethoxy)benzoate

[0456]

[0457] Iron powder (2.59 g, 46.5 mmol) and ammonium chloride (1.24 g, 23.2 mmol) were added to methyl 3-(2,2-difluoroethoxy)-2-nitrobenzene (1.85 g, 7.06 mmol) in THF (15 mL), methanol (15 mL), and water (5 mL). The reaction mixture was heated to 90 °C for 2 hours. Afterward, the reaction mixture was cooled to room temperature and analyzed by... The mixture was filtered and concentrated under vacuum. The residue was partitioned between ethyl acetate (60 mL) and water (60 mL). The combined organic layers were extracted, dried over magnesium sulfate, filtered, and the solvent was removed under vacuum to give the title compound (1.48 g, 91%) as a pale yellow oil.

[0458] LCMS (Method 3): [MH+] = 232, at 4.47 min.

[0459] Intermediate 23

[0460] Methyl 2-amino-5-bromo-3-(2,2-difluoroethoxy)benzoate

[0461]

[0462] At 0 °C, bromine (0.26 mL, 5.00 mmol) was added dropwise to a solution of methyl 2-amino-3-(2,2-difluoroethoxy)benzoate (1100 mg, 4.76 mmol) in chloroform (18 mL). The mixture was stirred at 0 °C for 1 hour. The reaction mixture was quenched with sodium thiosulfate and stirred for 10 minutes. A saturated sodium bicarbonate solution (6 mL) was added and the reaction was stirred for 5 minutes. The two phases were separated. The aqueous phase was extracted with DCM (2 × 50 mL). The combined organic phases were concentrated under vacuum to give the title compound (1354 mg, 93%) as a grayish-white solid.

[0463] 1H NMR (400MHz, CDCl3): δ7.68 (d, J = 2.3Hz, 1H), 6.93 (d, J = 2.0Hz, 1H), 6.27-5.96 (m, 3H), 4.25-4.16 (m, 2H), 3.88-3.87 (m, 3H).

[0464] Intermediate 24

[0465] Methyl 2-amino-3-(2,2-difluoroethoxy)-5-(5-fluoropyridin-2-yl)benzoate

[0466]

[0467] 4-fluoro-2-(tributyltinyl)pyridine (525 mg, 1.36 mmol) was added to dioxane (5 mL) containing methyl 2-amino-5-bromo-3-(2,2-difluoroethoxy)benzoate (422 mg, 1.36 mmol) and tetrakis(triphenylphosphine)palladium (0) (79 mg, 0.07 mmol). The reaction mixture was stirred at 100 °C for 16 hours under a nitrogen atmosphere. Afterward, the reaction mixture was poured into a 1 M potassium fluoride aqueous solution (10 mL) and stirred rapidly for 1 hour. The resulting suspension was then subjected to… Filter and wash with ethyl acetate (30 mL). Extract the organic layer from water (10 mL), wash with saturated sodium chloride aqueous solution (2 × 15 mL), dry over magnesium sulfate, filter, and remove solvent under vacuum. Purify the resulting residue by rapid silica gel column chromatography, eluting with a cyclohexane solution of 15% ethyl acetate, to give the title compound (261 mg, 59%) as a colorless solid.

[0468] ¹H NMR (400MHz, CDCl₃): δ 8.46 (d, J = 3.0Hz, ¹H), 8.09 (d, J = 1.9Hz, ¹H), 7.71–7.68 (m, 2H), 7.45–7.40 (m, 1H), 6.31–6.02 (m, 3H), 4.40–4.32 (m, 2H), 3.92 (s, 3H). LCMS (Method 4): [MH⁺] = 327 at 4.95 min.

[0469] Intermediate 25

[0470] 2-Amino-3-(2,2-difluoroethoxy)-5-(5-fluoropyridin-2-yl)benzoic acid

[0471]

[0472] Lithium hydroxide hydrate (29 mg, 1.22 mmol) was added to methyl 2-amino-3-(2,2-difluoroethoxy)-5-(5-fluoropyridin-2-yl)benzoate (266 mg, 0.82 mmol) in methanol (5 mL), THF (5 mL), and water (1 mL). The reaction mixture was stirred at 50 °C for 16 hours. Subsequently, the reaction mixture was concentrated under vacuum to give the title compound (282 mg, 100%) as a colorless solid.

[0473] 1H NMR (400MHz, DMSO): δ8.51(d,J=3.0Hz,1H),8.21(s,1H),7.83(dd,J=4.4,8.9Hz,1H), 7.72-7.66(m,1H),7.53-7.51(m,1H),6.44(tt,J=3.6,54.8Hz,1H),4.38-4.29(m,2H).

[0474] Intermediate 26

[0475] 8-(2,2-Difluoroethoxy)-6-(5-Fluoropyridin-2-yl)quinazolin-4(3H)-one

[0476]

[0477] Formamide (2 mL) was added to amino-3-(2,2-difluoroethoxy)-5-(5-fluoropyridin-2-yl)benzoic acid (220 mg, 0.71 mmol). The reaction mixture was stirred at 130 °C for 48 hours. The reaction mixture was then cooled to room temperature and poured into water (25 mL). The resulting solid was filtered, washed with water (10 mL), then with diethyl ether (15 mL), and air-dried to give the title compound (205 mg, 91%) as a colorless solid.

[0478] ¹H NMR (400MHz, DMSO): δ 12.42–12.40 (m, ¹H), 8.73 (d, J = 2.9 Hz, ¹H), 8.46 (d, J = 1.8 Hz, ¹H), 8.29 (dd, J = 4.3, 8.8 Hz, ¹H), 8.14 (s, ¹H), 8.08 (d, J = 1.8 Hz, ¹H), 7.94–7.87 (m, ¹H), 6.52 (tt, J = 3.7, 54.9 Hz, ¹H), 4.66–4.56 (m, 2H). LCMS (Method 3): [MH+] = 322, at 3.41 min.

[0479] Intermediate 27

[0480] 4-Chloro-8-(2,2-difluoroethoxy)-6-(5-fluoropyridin-2-yl)quinazolino

[0481]

[0482] DIPEA (402 mg, 3.11 mmol) was added to a toluene (7 mL) solution of 200 mg (200 mg, 0.62 mmol) of 8-(2,2-difluoroethoxy)-6-(5-fluoropyridin-2-yl)quinazolin-4(3H)-one. The reaction mixture was stirred at 120 °C for 10 min, and then phosphorus oxychloride (115 mg, 0.75 mmol) was added dropwise. The reaction mixture was then stirred at 120 °C for another 2 h. Subsequently, the reaction mixture was cooled to room temperature and the solvent was removed under vacuum. The resulting residue was partitioned between dichloromethane (10 mL) and a saturated aqueous solution of sodium bicarbonate (10 mL). The organic layer was separated, dried, filtered, and concentrated under vacuum to give the title compound (186 mg, 88%) as a pale brown solid, which was used directly in the next step.

[0483] Example 4

[0484] 8-(2,2-Difluoroethoxy)-6-(5-fluoropyridin-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine

[0485]

[0486] DIPEA (124 mg, 0.95 mmol) was added to a crude solution of 4-chloro-8-(2,2-difluoroethoxy)-6-(5-fluoropyridin-2-yl)quinazoline (65 mg, 0.19 mmol) and (6-methylpyridin-3-yl)methylamine (28 mg, 0.23 mmol) in 1,4-dioxane (3 mL). The reaction mixture was stirred at 50 °C for 16 h. The reaction mixture was then cooled to room temperature and the solvent was removed under vacuum. The resulting residue was purified by preparative HPLC to give the title compound (38 mg, 28%) as a grayish-white solid.

[0487] 1H NMR (400MHz, DMSO): δ9.20 (dd, J=5.8, 5.8Hz, 1H), 8.74 (d, J=3.0Hz, 1H), 8.6 7(d,J=1.5Hz,1H),8.48(s,1H),8.28(dd,J=4.1,8.9Hz,1H),8.06(d,J=1.4Hz ,1H),8.01-7.95(m,1H),7.58(d,J=8.7Hz,1H),7.51(d,J=8.8Hz,1H),6.54(t t,J=3.6,54.6Hz,1H),5.05(d,J=5.8Hz,2H),4.65-4.56(m,2H),2.61(s,3H). LCMS (Method 4): [MH+] = 427, at 2.77 min.

[0488] The following compounds reported in the table below were prepared according to the same procedure described for the preparation of 8-(2,2-difluoroethoxy)-6-(5-fluoropyridin-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine:

[0489]

[0490]

[0491] The following compounds reported in the table below were obtained as single isomers by chiral preparative SFC purification of the corresponding racemic mixtures, which were prepared according to the same procedure described for the preparation of 8-(2,2-difluoroethoxy)-6-(5-fluoropyridin-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine:

[0492]

[0493] Example 8

[0494] 8-(2,2-Difluoroethoxy)-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine

[0495]

[0496] Intermediate 28

[0497] 2-Amino-5-bromo-3-(2,2-difluoroethoxy)benzoic acid

[0498]

[0499] Methyl 2-amino-5-bromo-3-(2,2-difluoroethoxy)benzoate (1354 mg, 4.37 mmol) was dissolved in THF (30 mL) and methanol (30 mL). A solution of lithium hydroxide (157 mg, 6.55 mmol) in water (4 mL) was added, and the reaction was stirred at 50 °C for 18 hours. The reaction mixture was concentrated under vacuum to give the title compound (1351 mg, >100%) as an orange solid.

[0500] 1H NMR (400MHz, MeOD): δ7.56(d,J=2.3Hz,1H),6.89(d,J=2.3Hz,1H),6.25(t,J =3.9Hz, 1H), 6.12 (t, J = 3.8Hz, 1H), 5.98 (t, J = 3.8Hz, 1H), 4.17-4.08 (m, 2H).

[0501] Intermediate 29

[0502] 6-Bromo-8-(2,2-Difluoroethoxy)quinazolin-4-ol

[0503]

[0504] 2-Amino-5-bromo-3-(2,2-difluoroethoxy)benzoic acid (1250 mg, 4.22 mmol) was dissolved in formamide (12 mL). The reaction was stirred at 130 °C for 24 hours. The mixture was diluted with water and filtered. The solid was then washed with water, followed by washing with 9:1 diethyl ether / methanol to give the title compound (781 mg, 61%) as a light brown solid.

[0505] 1H NMR (400MHz, DMSO): δ 8.12-8.11 (m, 1H), 7.82 (d, J = 2.0Hz, 1H), 7.63-7.62 (m, 1H), 6.61-6.31 (m, 1H), 4.56-4.46 (m, 2H).

[0506] Intermediate 29a

[0507] 6-Bromo-4-chloro-8-(2,2-difluoroethoxy)quinazolino

[0508]

[0509] 6-Bromo-8-(2,2-difluoroethoxy)quinazolin-4-ol (400 mg, 1.31 mmol) was dissolved in toluene (14 mL), and DIPEA (1.1 mL, 6.56 mmol) was added. The mixture was heated to 90 °C for 5 minutes. Phosphorus oxychloride (V) (0.15 mL, 1.57 mmol) was added, and the reaction mixture was heated at 90 °C for 3 hours. The reaction mixture was concentrated under vacuum, and the residue was partitioned between DCM and sodium bicarbonate. The two phases were separated, and the aqueous phase was extracted with DCM (2 × 50 mL). The combined organic phases were concentrated under vacuum to give the title compound (502 mg, >100%) as a brown solid.

[0510] 1H NMR (400MHz, CDCl3): δ9.10-9.09 (m, 1H), 8.12-8.10 (m, 1H), 7.45 (d, J = 1.8Hz, 1H), 6.47-6.16 (m, 1H), 4.53-4.45 (m, 2H).

[0511] Intermediate 30

[0512] 6-Bromo-8-(2,2-difluoroethoxy)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine

[0513]

[0514] 6-Bromo-4-chloro-8-(2,2-difluoroethoxy)quinazoline (424 mg, 1.31 mmol) was dissolved in dioxane (6 mL). DIPEA (1.1 mL, 6.55 mmol) and (6-methylpyridazin-3-yl)methylamine (308 mg, 1.57 mmol) were added, and the reaction mixture was heated at 95 °C for 3 hours. The mixture was concentrated under vacuum, and the residue was partitioned between DCM and water. The two phases were separated. The aqueous phase was extracted with DCM (2 × 50 mL). The combined organic phases were concentrated under vacuum. The residue was purified by rapid silica gel column chromatography, eluting with 75% methanol in ethyl acetate, to give the title compound (374 mg, 70%) as a light brown solid.

[0515] 1H NMR (400MHz, DMSO): δ9.05-9.00(m,1H),8.45-8.44(m,1H),8.24-8.22(m,1H),7.55 -7.46(m,3H),6.49-6.47(m,1H),4.98-4.95(m,2H),4.57-4.46(m,2H),2.58(s,3H).

[0516] Example 8

[0517] 8-(2,2-Difluoroethoxy)-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine

[0518]

[0519] 6-Bromo-8-(2,2-difluoroethoxy)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (180 mg, 0.590 mmol), the complex of [1,1′-bis(diphenylphosphine)ferrocene]palladium(II) dichloride with dichloromethane (24 mg, 0.0295 mmol), bis(pinacol)diborone (180 mg, 0.708 mmol), and potassium acetate (69 mg, 0.708 mmol) were dissolved in dioxane (5 mL) and heated to 100 °C for 2 hours. An additional aliquot of 6-bromo-8-(2,2-difluoroethoxy)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine (50 mg, 0.122 mmol) was added, and the reaction mixture was further heated at 100 °C for 16 hours. The reaction mixture was allowed to cool to room temperature and the mixture was halved. 2-Bromo-5-methylpyridine (107 mg, 0.620 mmol), cesium carbonate (384 mg, 1.18 mmol), the complex of [1,1′-bis(diphenylphosphino)ferrocene]-palladium(II) dichloride with dichloromethane (24 mg, 0.0295 mmol), and water (2 mL) were added. The reaction mixture was heated at 100 °C for 2 hours. The reaction mixture was concentrated under vacuum, and the residue was partitioned between DCM and water. The two phases were separated, and the aqueous phase was extracted with DCM (2 × 50 mL). The combined organic phases were concentrated under vacuum. Purification by preparative HPLC gave the title compound (5 mg, 4%) as a white solid.

[0520] ¹H NMR (400MHz, DMSO): δ 9.23 (t, J = 5.7Hz, ¹H), 8.72–8.70 (m, ¹H), 8.62 (d, J = 2.0Hz, ¹H), 8.51–8.50 (m, ¹H), 8.18–8.13 (m, 2H), 7.88–7.84 (m, ¹H), 7.63–7.53 (m, 2H), 6.72–6.42 (m, ¹H), 5.11–5.07 (m, 2H), 4.69–4.60 (m, 2H), 2.65–2.64 (m, 3H), 2.44–2.43 (m, 3H). LCMS (Analysis Method 3): [MH + =423, at 4.01 min.

[0521] The following compounds reported in the table below were prepared according to the same procedure described for the preparation of 8-(2,2-difluoroethoxy)-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine (Example 8):

[0522]

[0523] Intermediate 31

[0524] 2-Amino-3-(morpholinylsulfonyl)benzoic acid

[0525]

[0526] 3-(chlorosulfonyl)-2-nitrobenzoic acid (0.75 g, 2.82 mmol) was added to a solution of morpholine (0.741 mL, 8.47 mmol) in water (50 mL) over 10 min and stirred for 30 min. Then, 10% (50% wet) Pd / C (2.82 mmol) and an aqueous 2N solution of hydrogen chloride (0.103 g, 2.82 mmol) were added, and the reaction was stirred overnight under a hydrogen atmosphere (balloon). The catalyst was filtered off and the solvent was removed under reduced pressure. The crude product was purified by C18 rapid chromatography ((H2O / ACN))95:5+0.1% HCOOH}:{(ACN / H2O)95:5+HCOOH 0.1%} from 100:0 to 0:100, yielding 2-amino-3-(morpholinylsulfonyl)benzoic acid (0.80 g, 2.79 mmol, 99% yield) as a brown solid.

[0527] LCMS (Method 5): 0.75 min. [M+H]+287.75

[0528] The following compounds reported in the table below were prepared by modifying the above procedure.

[0529]

[0530]

[0531]

[0532] Intermediate 37

[0533] Preparation of 2-amino-5-bromo-3-(morpholinylsulfonyl)benzoic acid

[0534]

[0535] NBS (0.567 mL, 2.79 mmol) was added to a solution of 2-amino-3-(morpholinylsulfonyl)benzoic acid (0.8 g, 2.79 mmol) in DMF, and the solution was stirred for 30 min. The solvent was then removed, and the crude product was purified by C18 rapid chromatography ((H2O / ACN) 95:5 + 0.1% HCOOH) : {(ACN / H2O) 95:5 + HCOOH 0.1%} from 100:0 to 0:100, providing 2-amino-5-bromo-3-(morpholinylsulfonyl)benzoic acid (0.85 g, 2.328 mmol, 83% yield) as a grayish-white solid.

[0536] LCMS (Method 5): 0.98 min, 366.56 [M+H]+

[0537] The following compounds reported in the table below were prepared by modifying the above procedure.

[0538]

[0539]

[0540] Intermediate 43

[0541] 6-Bromo-8-(morpholinylsulfonyl)quinazolin-4-ol

[0542]

[0543] Ethanesulfonic acid (0.6 ml, 1.643 mmol) was added to a solution of 2-amino-5-bromo-3-(morpholinylsulfonyl)benzoic acid (600 mg, 1.643 mmol) (intermediate 35) in formamide (6 ml), and the mixture was heated to 120°C for 48 h. The reaction was directly loaded onto a C18 column and subjected to reversed-phase chromatography ((H2O / ACN)) 95:5 + 0.1% HCOOH:{(ACN / H2O) 95:5 + HCOOH 0.1%} from 100:0 to 0:100 to give 6-bromo-8-(morpholinylsulfonyl)quinazolin-4-ol (0.230 g, 0.615 mmol, 37.4% yield) as a brown solid.

[0544] LCMS (Method 5): 0.72 min [M+H] + 375.56

[0545] The following compounds reported in the table below were prepared by modifying the above procedure.

[0546]

[0547]

[0548] Intermediate 50

[0549] 6-(4-Fluorophenyl)-8-(morpholinylsulfonyl)quinazolin-4-ol

[0550]

[0551] To a suspension of 6-bromo-8-(morpholinylsulfonyl)quinazoline-4-ol (250 mg, 0.668 mmol) in dioxane (10 ml), water (3 ml), 4-fluorophenylboronic acid (187 mg, 1.336 mmol), K₂CO₃ (277 mg, 2.004 mmol), and PdCl₂ (dppf) (56 mg, 0.07 mmol) were added, and the reaction was stirred overnight. The solvent was then removed, and the crude product was purified by C18 rapid chromatography ((H₂O / ACN) 95:5 + 0.1% HCOOH}:{(ACN / H₂O) 95:5 + HCOOH 0.1%} from 100:0 to 0:100, yielding 6-(4-fluorophenyl)-8-(morpholinylsulfonyl)quinazoline-4-ol (204 mg, 0.524 mmol, 78% yield) as a brown solid.

[0552] LCMS (Method 5): 0.87 min, [M+H]+389.81.

[0553] The following compounds reported in the table below were prepared by modifying the above procedure.

[0554]

[0555]

[0556] Example 10

[0557] (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(morpholinylsulfonyl)quinazolin-4-amine

[0558]

[0559] Add PyBOP (96 mg, 0.185 mmol) and DIPEA (0.059 ml, 0.339 mmol) to a solution of 6-(4-fluorophenyl)-8-(morpholinylsulfonyl)quinazolin-4-ol (60 mg, 0.154 mmol) in dry DMF (4 ml), and stir the reaction for 30 min. Then, ((R)-1-(6-methylpyridazin-3-yl)ethyl-1-amine dihydrochloride (32.4 mg, 0.154 mmol) was added, and the reaction was stirred further for 30 min. The solvent was then removed, and the crude product was purified by C18 rapid chromatography ((H2O / ACN))95:5+0.1% HCOOH}:{(ACN / H2O)95:5+HCOOH 0.1%} from 100:0 to 0:100, providing (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(morpholinylsulfonyl)quinazolin-4-amine (10 mg, 0.020 mmol, 12.76% yield) as a pale yellow solid.

[0560] 1 H NMR(400MHz, DMSO-d6)δppm 9.20(s,2H),9.01(br d,J=6.58Hz,1H),8.95(s,1H),8.56(s,1H),8.54(s,1H),7.92(br dd,J=8.22,5.59Hz,2H),7.43(br t,J=8.66Hz,2H),5.71(br quin,J=6.80Hz,1H),4.33(br t,J=4.82Hz,2H),3.52-3.61(m,4H),3.39-3.50(m,2H),1.75(br d,J=7.02Hz,3H)

[0561] LCMS (Method 5): 1.58 min, 509.13 [M+H]+

[0562] The following compounds, reported in the table below, were prepared by adjusting the above procedure using appropriate intermediates.

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570] Example 24

[0571] (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(piperazin-1-ylsulfonyl)quinazolin-4-amine

[0572]

[0573] PyBOP (129 mg, 0.249 mmol) and DIPEA (0.100 mL, 0.574 mmol) were added to a solution of 4-((6-(4-fluorophenyl)-4-hydroxyquinazoline-8-yl)sulfonyl)piperazine-1-carboxylic acid benzyl ester (100 mg, 0.191 mmol) (intermediate 55) in dry DMF (5 mL), and the reaction was stirred for 30 min. Then, (R)-1-(6-methylpyridazine-3-yl)ethyl-1-amine dihydrochloride (40.2 mg, 0.191 mmol) was added, and the reaction was stirred for another 30 min. The solvent was removed, and the crude product was redissolved in dry DCM (5.00 mL) and a 1 M boron tribromide DCM solution (1.914 mL, 1.914 mmol) was added, and the reaction was stirred for 1 h. EtOH (2 mL) was added, and the volatiles were removed. The crude product was purified by C18 rapid chromatography ((H2O / ACN) 95:5 + 0.1% HCOOH}:{(ACN / H2O) 95:5 + HCOOH 0.1%} from 100:0 to 0:100, providing (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(piperazin-1-ylsulfonyl)quinazolin-4-amine (7 mg, 0.014 mmol, 7.21% yield) as a white solid.

[0574] 1H NMR(400MHz,DMSO-d6)δppm 9.25(br d,J=6.58Hz,1H),9.08(d,J=1.75Hz,1H),8.64(br s,2H),8.54(d,J=1.75Hz,1H),8.50(s,1H),7.88-7.98(m,3H),7.76(d,J=8.77Hz, 1H),7.41(t,J=8.77Hz,2H),5.76(quin,J=6.96Hz,1H),3.46-3.58(m,4H),3.09(br s,4H),2.62(s,3H),1.71(d,J=7.02Hz,3H)

[0575] UPLC PRECLI-WI-0183minuti rt 4.29min 508.18m / z

[0576] The following compounds reported in the table below were prepared by modifying the above procedure.

[0577]

[0578] Intermediate 56

[0579] Methyl 4-amino-4'-fluoro-[1,1'-biphenyl]-3-carboxylate

[0580]

[0581] Nitrogen gas was bubbled through a mixture of methyl 2-amino-5-bromobenzoate (2.00 g, 8.69 mmol), 4-fluorophenylboronic acid, pinacol ester (2.90 g, 12.04 mmol), tripotassium phosphate (3.69 g, 17.39 mmol), and water (3.5 mL) in N,N-dimethylformamide (10.5 mL) for 5 min. Then, a complex of [1,1′-bis(diphenylphosphino)ferrocene]-palladium(II) dichloride with dichloromethane (710 mg, 0.87 mmol) was added. The resulting mixture was heated to 100 °C for 1.25 h. After returning to room temperature, the reaction mixture was diluted with water (100 mL) and diethyl ether (100 mL) and the organic phase was separated. The aqueous phase was further extracted with diethyl ether (100 mL) and then with ethyl acetate (100 mL). The organic phases were combined, washed with water (100 mL), dried over MgSO4, and the solvent was removed under vacuum. The residue was purified by silica gel chromatography by elution with a cyclohexane solution of 5-35% ethyl acetate to give the title compound (2.08 g, 97%) as a grayish-white solid.

[0582] 1H NMR (400MHz, CDCl3): δ8.06(d,J=2.3Hz,1H),7.50-7.44(m,3H),7.08(dd,J=8.7,8.7Hz,2H),6.74(d,J=8.6Hz,1H),5.78(s,2H),3.90(s,3H).

[0583] Intermediate 57

[0584] methyl 4-amino-4'-fluoro-5-iodo-[1,1'-biphenyl]-3-carboxylate

[0585]

[0586] To a solution of methyl 4-amino-4'-fluoro-[1,1'-biphenyl]-3-carboxylate (2.08 g, 8.48 mmol) in dichloromethane (25 mL), bis(pyridine)iodonium tetrafluoroborate (4.73 g, 12.72 mmol) and TFA (2.1 mL, 27.42 mmol) were added. The resulting mixture was stirred at room temperature for 2 days. HPLC analysis showed a 70% conversion, and further addition of bis(pyridine)iodonium tetrafluoroborate (1.25 g, 3.36 mmol) and stirring were maintained for another 2.5 hours. The reaction mixture was diluted with dichloromethane (25 mL) and carefully treated with a solution of NaHCO3 (7 g, 83 mmol) in water (100 mL). The aqueous layer was collected and further extracted with dichloromethane (2 × 25 mL). The organic phases were combined, washed with 100 mL of 8% sodium thiosulfate aqueous solution, filtered through a hydrophobic glass buffer, and the solvent was removed under vacuum. The residue was purified by silica gel chromatography by elution with a cyclohexane solution of 0–25% ethyl acetate to give the title compound (2.71 g, 86%) as a grayish-white solid.

[0587] 1H NMR (400MHz, CDCl3): δ 8.10-8.07 (m, 1H), 8.04-8.00 (m, 1H), 7.46-7.41 (m, 2H), 7.09 (dd, J = 8.6, 8.6Hz, 2H), 6.48-6.37 (m, 2H), 3.91 (s, 3H).

[0588] Intermediate 58

[0589] 4-Amino-4'-fluoro-5-iodo-[1,1'-biphenyl]-3-carboxylic acid

[0590]

[0591] Lithium hydroxide monohydrate (1.75 g, 41.87 mmol) was added to a solution of methyl 4-amino-4'-fluoro-5-iodo-[1,1'-biphenyl]-3-carboxylate (2.59 g, 6.98 mmol) in 1,4-dioxane (25 mL) and water (5 mL). The mixture was stirred at room temperature for 18 hours. The reaction mixture was diluted with water (100 mL) and ether (100 mL) and separated. The aqueous phase was acidified to pH 1 with 1N HCl (45 mL) and extracted with dichloromethane (3 × 50 mL). The organic phases were combined, filtered through a hydrophobic glass frit, and the solvent was removed under vacuum to give the title compound (2.39 g, 96%) as a grayish-white solid.

[0592] 1H NMR (400MHz, DMSO): δ 13.17 (s, 1H), 8.18 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 2.3 Hz, 1H), 7.65 (dd, J = 5.4, 8.5 Hz, 2H), 7.27 (dd, J = 8.8, 8.8 Hz, 2H), 6.84 (s, 2H).

[0593] Intermediate 59

[0594] 6-(4-Fluorophenyl)-8-iodoquinazolin-4(3H)-one

[0595]

[0596] A solution of 4-amino-4'-fluoro-5-iodo-[1,1'-biphenyl]-3-carboxylic acid (2.39 g, 6.69 mmol) in formamide (4 mL) was heated to 130 °C for 16 hours. After returning to room temperature, the reaction mixture was diluted with water (20 mL) and stirred for 20 minutes, then filtered. The solid was washed with water (3 × 5 mL) and then with 10% MeOH in diethyl ether (3 × 5 mL) to give the title compound (2.14 g, 87%) as a grayish-white solid.

[0597] 1H NMR (400MHz, DMSO): δ 12.57 (s, 1H), 8.66 (s, 1H), 8.36 (s, 1H), 8.28 (s, 1H), 7.89 (dd, J = 5.6, 7.8Hz, 2H), 7.38 (dd, J = 8.6, 8.6Hz, 2H).

[0598] Intermediate 60

[0599] 6-(4-Fluorophenyl)-8-(methylthio)quinazolin-4-ol

[0600]

[0601] Add sodium methanethiol (0.096 g, 1.366 mmol), copper iodide (I) (0.260 g, 1.366 mmol), and cyclohexane-1,2-diamine (0.156 g, 1.366 mmol) to a solution of 6-(4-fluorophenyl)-8-iodoquinazolin-4-ol (0.5 g, 1.366 mmol) in dry DMSO (5 ml), and stir the reaction overnight at 130°C. The crude product was directly loaded onto a C18 column and subjected to reversed-phase chromatography ((H2O / ACN))95:5+0.1% HCOOH}:{(ACN / H2O)95:5+HCOOH 0.1%} from 100:0 to 0:100 to give 6-(4-fluorophenyl)-8-(methylthio)quinazolin-4-ol (0.25 g, 0.873 mmol, 63.9% yield) as a brown solid.

[0602] LCMS (Method 5): 0.96 min, 286.75 [M+H]+

[0603] Example 26

[0604] (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(methylthio)quinazolin-4-amine CRDD456-64-1

[0605]

[0606] PyBOP (95 mg, 0.182 mmol) and DIPEA (0.073 mL, 0.419 mmol) were added to a solution of 6-(4-fluorophenyl)-8-(methylthio)quinazolin-4-ol (40 mg, 0.140 mmol) in dry DMF (4 mL), and the reaction was stirred for 30 min. Then, (R)-1-(6-methylpyridazin-3-yl)ethyl-1-amine dihydrochloride (29.4 mg, 0.140 mmol) was added, and the reaction was stirred for another 30 min. The solvent was then removed and the crude product was purified by C18 rapid chromatography ((H2O / ACN))95:5+0.1%HCOOH}:{(ACN / H2O)95:5+HCOOH 0.1%} from 100:0 to 0:100, providing (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(methylthio)quinazolin-4-amine (6 mg, 0.015 mmol, 10.59% yield) as a white solid.

[0607] 1H NMR(600MHz,DMSO-d6)δppm 8.77(d,J=7.56Hz,1H),8.45(d,J=1.64Hz,1H),8.40(s,1H),7.96(t,J=6.54Hz,2H),7.68(d,J=1.64Hz,1H),7.61(d,J=8.88 Hz,1H),7.49(d,J=8.55Hz,1H),7.39(t,J=8.88Hz,2H),5.74-5.79(m,1H),2.58(s,3H),2.56(s,3H),1.71(d,J=7.23Hz,3H)

[0608] UPLC PRECLI-WI-0183minuti rt 5.98min 406.23m / z

[0609] Intermediate 61

[0610] 6-(4-Fluorophenyl)-8-(Methylsulfinyl)quinazolin-4-ol CRDD456-65-1

[0611]

[0612] To a solution of 6-(4-fluorophenyl)-8-(methylthio)quinazolin-4-ol (100 mg, 0.349 mmol) in dry DCM (5 mL), mCPBA (60.3 mg, 0.349 mmol) was added, and the reaction was stirred for 1 hour. The reaction mixture was then diluted in DCM (20 mL) and washed with saturated aqueous solutions of Na₂SO₃ (20 mL) and NaHCO₃ (20 mL). The organic phase was dried over Na₂SO₄, filtered, and the solvent was removed under reduced pressure. The crude product was purified by C18 rapid chromatography ((H2O / ACN) 95:5 + 0.1% HCOOH) : {(ACN / H2O) 95:5 + HCOOH 0.1%} from 100:0 to 0:100, yielding 6-(4-fluorophenyl)-8-(methylsulfinyl)quinazolin-4-ol (55 mg, 0.182 mmol, 52.1% yield).

[0613] LCMS (Method 5): 1.16 min, 302.75 [M+H]+

[0614] Example 27

[0615] 6-(4-Fluorophenyl)-N-((R)-1-(6-methylpyridazin-3-yl)ethyl)-8-(methylsulfinyl)quinazolin-4-amine

[0616]

[0617] PyBOP (112 mg, 0.215 mmol) and DIPEA (0.087 mL, 0.496 mmol) were added to a solution of 6-(4-fluorophenyl)-8-(methylsulfinyl)quinazolin-4-ol (50 mg, 0.165 mmol) (intermediate 61) in dry DMF (4 mL), and the reaction was stirred for 30 min. Then, (R)-1-(6-methylpyridazin-3-yl)ethyl-1-amine dihydrochloride (38.2 mg, 0.182 mmol) was added, and the reaction was stirred for another 30 min. The solvent was then removed and the crude product was purified by C18 rapid chromatography ((H2O / ACN))95:5+0.1%HCOOH}:{(ACN / H2O)95:5+HCOOH 0.1%} from 100:0 to 0:100, providing 6-(4-fluorophenyl)-N-((R)-1-(6-methylpyridazin-3-yl)ethyl)-8-(methylsulfinyl)quinazolin-4-amine (5 mg, 0.012 mmol, 7.17% yield) as a white solid.

[0618] 1H NMR(600MHz,DMSO-d6)δppm 9.05-9.10(m,1H),8.93(dd,J=5.09,2.06Hz,1H),8.45(d,J=5.22Hz,1H),8.34(d,J=1.92Hz,1H),7.95(t,J=6.73Hz,2H),7.65(d,J=8. 80Hz,1H),7.50(d,J=8.52Hz,1H),7.44(t,J=8.80Hz,2H),5.75-5.81(m,1H),2.90-2.93(m,3H),2.58-2.59(m,3H),1.73(d,J=7.01,3H)

[0619] UPLC PRECLI-WI-0183minuti rt 5.16min 422.24m / z

[0620] Intermediate 61a

[0621] (R)-6-(4-fluorophenyl)-8-iodo-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine

[0622]

[0623] To a solution of 6-(4-fluorophenyl)-8-iodoquinazolin-4-(3H)-one (1.14 g, 3.11 mmol) in N,N-dimethylformamide (10 mL), phosphonium hexafluorophosphate (2.03 g, 1.25 mmol) and diisopropylethylamine (2.7 mL, 15.57 mmol) were added sequentially. The resulting mixture was heated to 45 °C for one hour, followed by the addition of (R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl-1-amine hydrochloride (0.96 g, 4.2 mmol), and heating was maintained at 45 °C for 2 hours. After returning to room temperature, the mixture was diluted with ethyl acetate (75 mL) and water (175 mL). The organic phase was washed with brine (2 × 20 mL), passed through a hydrophobic glass frit, and the solvent was removed under vacuum. The residue was purified by silica gel chromatography by elution with a dichloromethane solution of 0-15% ethyl acetate to give the title compound (1.27 g, 75%) as a grayish-white solid.

[0624] 1H NMR (400MHz, DMSO): δ9.18(s,2H),8.88(d,J=6.9Hz,1H),8.71(d,J=1.8Hz,1H),8.67(d,J=1.8Hz,1H), 8.51(s,1H),7.95-7.90(m,2H),7.40(dd,J=8.9,8.9Hz,2H),5.73-5.67(m,1H),1.75(d,J=7.2Hz,3H).

[0625] The following compounds, reported in the table below, were prepared using appropriate amines with modifications to the above procedure.

[0626]

[0627]

[0628] Example 28

[0629] (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(oxetane-3-ylthio)quinazolin-4-amine

[0630]

[0631] To a solution of (R)-6-(4-fluorophenyl)-8-iodo-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine (400 mg, 0.824 mmol) (intermediate 61b) in dry oxetane-3-thiol (74.3 mg, 0.824 mmol), copper iodide (I) (7.85 mg, 0.041 mmol), cyclohexane-1,2-diamine (0.020 mL, 0.165 mmol), and potassium phosphate (525 mg, 2.473 mmol) were added, and the reaction was stirred overnight at 130°C. The reaction was directly loaded onto a C18 column and subjected to reversed-phase chromatography ((H2O / ACN))95:5+0.1%HCOOH}:{(ACN / H2O)95:5+HCOOH 0.1%} from 100:0 to 0:100 to give (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(oxecyclobutane-3-ylthio)quinazolin-4-amine (100 mg, 0.223 mmol, 27.1% yield) as a brown solid.

[0632] UPLC PRECLI-WI-0183minuti rt 4.22min 448.25m / z

[0633] 1 H NMR(600MHz,DMSO-d6)δppm 8.13(dd,J=2.14,1.48Hz,1H),7.90(s,1H),7.78(dd,J=12.00,8.71Hz,1H),7.70-7.75(m,2H),7.67-7.69(m,1H),7.49(dd,J=8.88,2.96Hz,1 H),7.30-7.34(m,2H),5.68-5.75(m,1H),5.35-5.41(m,1H),4.19-4.28 (m,2H),3.50-3.66(m,2H),2.58(s,3H),1.45(dd,J=6.74,4.77Hz,3H).

[0634] Example 29

[0635] 6-(4-Fluorophenyl)-N-((R)-1-(6-methylpyridazin-3-yl)ethyl)-8-(oxetane-3-ylsulfinyl)quinazolin-4-amine

[0636]

[0637] mCPBA (38.6 mg, 0.223 mmol) was added to a solution of (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(oxecyclobutane-3-ylthio)quinazolin-4-amine (100 mg, 0.223 mmol) in dried DCM (5 mL), and the reaction was stirred for 1 h. The reaction was then diluted in DCM (20 mL) and washed with saturated Na₂SO₃ solution (20 mL) and saturated NaHCO₃ aqueous solution (20 mL). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was subjected to rapid C18 chromatography ((H2O / ACN) 95:5 + 0.1% HCOOH}:{(ACN / H2O) 95:5 + HCOOH 0.1%} from 100:0 to 0:100 to obtain 6-(4-fluorophenyl)-N-((R)-1-(6-methylpyridazin-3-yl)ethyl)-8-(oxetane-3-ylsulfinyl)quinazolin-4-amine (10 mg, 0.022 mmol, 9.65% yield) as a pale yellow solid.

[0638] LCMS (Method 5): 0.65 min, 467.27 [M+H]+

[0639] 1 H NMR (600MHz, DMSO-d6) δppm 8.59 (br s, 1H), 8.39 (d, J = 1.65Hz, 1H), 8.00-8.08 (m, 1H), 7.75-7.89 (m, 3H), 7.50 (br d,J=8.52Hz,1H),7.36(t,J=8.25Hz,2H),5.71-5.78(m,1H),5.36-5.41(m,1H),4 .18-4.22(m,2H),3.58-3.80(m,2H),2.62(s,3H),1.47(dd,J=6.74,3.16Hz,3H).

[0640] Intermediate 62

[0641] (R)-6-(4-fluorophenyl)-8-((tetrahydro-2H-pyran-4-yl)oxy)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine

[0642]

[0643] Nitrogen gas was bubbled through a mixture of (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-ol (40 mg, 0.01 mmol) (intermediate 10), tetrahydro-4-pyranol (10 mg, 0.102 mmol), and cyanomethyltributylphosphine (1 M, in toluene, 0.14 mL, 0.14 mmol) in toluene (3.0 mL) for 5 min. The mixture was heated to 100 °C for 72 h. After returning to room temperature, the solvent was removed under vacuum. The residue was purified by preparative HPLC to give the title compound (17 mg, 38%) as a grayish-white solid.

[0644] ¹H NMR (400MHz, DMSO): δ 9.18 (s, 2H), 8.64 (d, J = 7.0Hz, 1H), 8.44 (s, 1H), 8.23 ​​(d, J = 1.6Hz, 1H), 7.94–7.89 (m, 2H), 7.65 (d, J = 1.6Hz, 1H), 7.39 (dd, J = 8.8, 8.8Hz, 2H), 5.71–5.66 (m, 1H), 5.02–4.94 (m, 1H), 3.96–3.88 (m, 2H), 3.51 (dd, J = 9.7, 9.7Hz, 2H), 2.07–2.00 (m, 2H), 1.74 (d, J = 7.0Hz, 5H). LCMS (Method 3): [MH+] = 514 at 3.79 min.

[0645] The following compounds reported in the table below were prepared according to the same procedure described for the preparation of (R)-6-(4-fluorophenyl)-8-((tetrahydro-2H-pyran-4-yl)oxy)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazoline-4-amine:

[0646]

[0647]

[0648]

[0649]

[0650] Intermediate 63

[0651] (R)-8-((3-(benzyloxy)isoxazo-5-yl)methoxy)-6-(4-fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine

[0652]

[0653] Nitrogen gas was bubbled through a mixture of (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-ol (95 mg, 0.221 mmol), (3-(benzyloxy)isoxazol-5-yl)methanol (75 mg, 0.265 mmol), and cyanomethyltributylphosphonane (64 mg, 0.265 mmol) in toluene (4.0 mL) for 5 min. The mixture was heated to 100 °C for 72 h. After returning to room temperature, the solvent was removed under vacuum. The residue was purified by preparative HPLC to give the title compound (140 mg) as a grayish-white solid, which was used for the next step without further purification.

[0654] Example 38

[0655] (R)-5-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)isoxazo-3-ol

[0656]

[0657] A mixture of (R)-8-((3-(benzyloxy)isoxazol-5-yl)methoxy)-6-(4-fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine (140 mg, 0.227 mmol) in acetic acid (1 mL) was added to an aqueous solution of 48% hydrogen bromide (2 mL). The mixture was heated at 100 °C for 2 hours. After returning to room temperature, the reaction was evaporated under vacuum and the residue was purified by preparative HPLC to give the title compound (3.2 mg, 2.7%, in two steps) as a grayish-white solid.

[0658] ¹H NMR (400MHz, DMSO): δ 9.18 (s, 2H), 8.69 (d, J = 6.9Hz, 1H), 8.43 (s, 1H), 8.28 (d, J = 1.4Hz, 1H), 7.97–7.92 (m, 2H), 7.71 (d, J = 1.4Hz, 1H), 7.41 (dd, J = 8.9, 8.9Hz, 2H), 6.16 (s, 1H), 5.72–5.66 (m, 1H), 5.41 (s, 2H), 1.74 (d, J = 7.2Hz, 3H). OH was not observed. LCMS (Method 3): [MH+] = 527 at 3.60 min.

[0659] Intermediate 64

[0660] (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)tert-butyl acetate

[0661]

[0662] 2-Bromoacetic acid tert-butyl ester (0.057 ml, 0.384 mmol) was added to a stirred mixture of (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazoline-8-ol (150 mg, 0.349 mmol) (intermediate 10) and potassium carbonate (155 mg, 1.122 mmol) in DMF (3 ml). Stirring was continued for 1 h at room temperature, and the reaction mixture was then diluted with EtOAC and washed with brine (2×). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 10 g KP-Sil column, eluted 15 CV with a dichloromethane solution of 0 to 50% EtOAc) to give (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)tert-butyl acetate as a white powder (149 mg, 0.274 mmol, 78% yield).

[0663] LCMS (Method 5): 0.97 min, m / z 544.2 [M+H]+.

[0664] Intermediate 65

[0665] (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetic acid

[0666]

[0667] (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazoline-8-yl)oxy)acetic acid tert-butyl ester (149 mg, 0.274 mmol) was dissolved in TFA (2 mL). The mixture was stirred at room temperature for 16 h, and then the volatiles were removed under reduced pressure. The solution was ground in diethyl ether to give (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazoline-8-yl)oxy)acetic acid (134 mg, 0.275 mmol, 100% yield) as a pale pink powder.

[0668] LCMS (Method 5): 0.81 min, m / z 488.1 [M+H]+,

[0669] 1 ¹H NMR (400MHz, DMSO-d6) δppm 9.22 (bs, 1H), 9.16 (s, 2H), 8.55 (s, 1H), 8.29 (s, 1H), 7.87 (dd, J = 8.66, 5.37Hz, 2H), 7.65 (br s, 1H), 7.38 (t, J = 8.77Hz, 2H), 5.75 (quintet, J = 6.63Hz, 1H), 5.07 (s, 2H), 1.73 (d, J = 7.02Hz, 3H).

[0670] Example 40

[0671] (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)-N-(phenylsulfonyl)acetamide

[0672]

[0673] EDCI (67.8 mg, 0.354 mmol) was added to a stirred solution of (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetic acid (115 mg, 0.236 mmol) (intermediate 65), DIPEA (205 μl, 1.180 mmol), benzenesulfonamide (55.6 mg, 0.354 mmol), and DMAP (43.2 mg, 0.354 mmol) in DMF (2 mL). Stirring was continued for 16 h at room temperature. The reaction mixture was diluted with EtOAc, and then formic acid (100 μl, 2.65 mmol) was added. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by column chromatography (Biotage Isolera, 30 g C18 column, eluting with a gradient of 0 to 60% B in solution A; A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH) to give (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)-N-(phenylsulfonyl)acetamide as a grayish-white powder (97.3 mg, 0.155 mmol, 65.8% yield).

[0674] LCMS (Method 5): 0.96 min, 627.2 [M+H]+

[0675] 1 H NMR(400MHz,DMSO-d6)δppm 9.14(s,2H),8.97(br s,1H),8.44(s,1H),8.24(s,1H),8.10(s,1H),7.72-7.88(m,4H),7.30-7.55(m,6H),5.65-5.74(m,1H),4.85-4.99(m,2H),2.64(br s,1H),2.50-1.71(d,J=7.23Hz,3H)

[0676] Intermediate 66

[0677] (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid ethyl ester

[0678]

[0679] Cesium carbonate (152 mg, 0.466 mmol) was added to a stirred mixture of ethyl 1-(bromomethyl)cyclopropane-1-carboxylate (0.053 mL, 0.256 mmol) and (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazoline-8-ol (100 mg, 0.233 mmol) (intermediate 10) in DMF (2 mL). The reaction mixture was stirred at 60 °C for 4 h, then diluted with AcOEt and washed with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 28 g NH column, gradient elution with dichloromethane solution from 0 to 10% ethyl acetate for 15 CV) to give (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid ethyl ester (68.1 mg, 0.123 mmol, 52.6% yield).

[0680] LCMS (Method 5): 0.96 min, 556.1 m / z [M+H]+

[0681] Example 41

[0682] (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0683]

[0684] A solution of lithium hydroxide (15.2 mg, 0.635 mmol) in water (1 mL) was added to a solution of (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid ethyl ester (68.1 mg, 0.123 mmol) in THF (3 mL). Stirring was continued for 16 h at room temperature. Volatile substances were removed under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 30 g C18 column, gradient elution of solution A from 0 to 45% B, A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH, 15 CV) to give (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid as a grayish-white powder (5.1 mg, 9.67 μmol, 7.89% yield).

[0685] LCMS (Method 5): 0.80 min, 527.8 m / z [M+H]+

[0686] 1 ¹H NMR (400MHz, DMSO-d⁶) δppm 12.34–12.62 (bs, 1H), 9.12 (s, 2H), 8.57 (br d, J = 7.02 Hz, 1H), 8.38 (s, 1H), 8.13–8.18 (m, 1H), 7.85–7.95 (m, 2H), 7.48 (s, 1H), 7.34 (t, J = 8.77 Hz, 2H), 5.64 (quintet, J = 6.85 Hz, 1H), 4.30 (s, 2H), 1.69 (d, J = 7.02 Hz, 3H), 1.01–1.28 (m, 4H).

[0687] Example 42

[0688] 1-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)methyl cyclopropane-1-carboxylate

[0689]

[0690] Methyl 1-(2-chloroacetamido)cyclopropane-1-carboxylate (49.6 mg, 0.259 mmol) was added to a stirred mixture of 6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazoline-8-ol (85 mg, 0.235 mmol) (intermediate 11) and potassium carbonate (98 mg, 0.706 mmol) in DMF (3 mL). Stirring was continued at 80 °C for 16 h. The reaction mixture was then diluted with THF and washed with a saturated aqueous ammonium chloride solution, followed by washing with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 28 g NH column, eluting with a gradient of 0 to 30% B in solution A; A: dichloromethane, B: dichloromethane / MeOH 90:10) to give methyl 1-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamyl)cyclopropane-1-carboxylate as a grayish-white powder (44.0 mg, 0.085 mmol, 36.2% yield).

[0691] LCMS (Method 5): 0.60 min, m / z 517.2 [M+H]+

[0692] 1 H NMR(400MHz,DMSO-d6)δppm 9.03-9.12(m,2H),8.43(s,1H),8.23-8.28(m,1H),7.88(dd,J=8.77,5.48Hz,2H),7.59-7.67(m,1H),7.43-7.55(m,2H),7. 35(t,J=8.88Hz,2H),5.00(d,J=5.48Hz,2H),4.79(s,2H),3.43(s,3H),2.56(s,3H),1.25-1.45(m,2H),0.98-1.11(m,2H).

[0693] The following compounds were prepared by adjusting the above procedure starting from the substrates reported in the table.

[0694]

[0695]

[0696] Example 44

[0697] (R)-1-(2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopropane-1-carboxylic acid

[0698]

[0699] 2N LiOH (0.2 mL, 0.400 mmol) was added to a stirred solution of (R)-1-(2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopropane-1-carboxylate (50.9 mg, 0.087 mmol) (Example 43) in THF (3 mL). Stirring was continued at 80 °C for 16 h. Volatiles were removed under reduced pressure, and DMF (2 mL) was added to the residue, followed by formic acid (20 μl, 0.530 mmol). The resulting suspension was purified by chromatography (Biotage Isolera, 12 g C18 Ultra column, eluting with a gradient of 0 to 35% B in solution A; A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH) to give (R)-1-(2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetamyl)cyclopropane-1-carboxylic acid (9.9 mg, 0.017 mmol, 19.93% yield) as a white powder.

[0700] LCMS (Method 5): 0.77 min, m / z 570.8 [M+H]+

[0701] 1 ¹H NMR (400MHz, DMSO-d⁶) δppm 11.90–12.82 (bs, 1H), 9.13 (s, 2H), 8.90 (s, 1H), 8.67 (br d, J = 7.02 Hz, 1H), 8.43 (s, 1H), 8.26 (s, 1H), 7.88 (dd, J = 8.77, 5.48 Hz, 2H), 7.61 (s, 1H), 7.35 (t, J = 8.77 Hz, 2H), 5.66 (quintet, J = 6.80 Hz, 1H), 4.75 (s, 2H), 1.70 (d, J = 7.23 Hz, 3H), 1.23–1.40 (m, 2H), 0.90–1.03 (m, 2H).

[0702] Intermediate 67a

[0703] Sodium salt of 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetic acid

[0704]

[0705] NaOH (10.5 mg, 0.26 mmol) was added to ethyl 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetate (117 mg, 0.26 mmol) in MeOH (2.2 mL) (intermediate 67). The mixture was stirred at room temperature for 3 days, then diluted with diethyl ether and filtered to give sodium 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetate as a white powder (87 mg, 75% yield).

[0706] Intermediate 68

[0707] (1R,2S)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopentane-1-carboxylic acid ethyl ester

[0708]

[0709] PyAOP (82 mg, 0.157 mmol) was added to a mixture of 2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetic acid (55 mg, 0.131 mmol) (intermediate 67a), (1R,2S)-2-aminocyclopentane-1-carboxylic acid ethyl ester (24.74 mg, 0.157 mmol), and DIPEA (0.069 mL, 0.393 mmol) in THF (3 mL). Stirring was continued for 1 h at room temperature. The reaction mixture was diluted with AcOEt and then washed with saturated aqueous ammonium chloride solution, saturated aqueous sodium bicarbonate solution, and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 28 g NH column, eluting 25 CV with a gradient of 0 to 100% EtOAc in dichloromethane solution), followed by RP chromatography (Biotage Isolera, 12 g C18 Ultra column, eluting 25 CV with a gradient of 0 to 35% B in A solution; A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH) to give (1R,2S)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamyl)cyclopentane-1-carboxylic acid ethyl ester as a grayish-white powder (21.4 mg, 0.038 mmol, 29.2% yield).

[0710] LCMS (Method 5): 0.72 min, 559.4 [M+H]+.

[0711] 1 H NMR(400MHz,DMSO-d6)δppm 9.11(t,J=5.81Hz,1H),8.48(d,J=8.55Hz,1H),8.41(s,1H),8.26(d,J=1.53Hz,1H),7.84-7 .91(m,2H),7.72(d,J=1.53Hz,1H),7.49-7.53(m,1H),7.44-7.49(m,1H),7.34(t,J=8.88Hz, 2H),5.01(d,J=5.70Hz,2H),4.70-4.79(m,2H),4.36-4.43(m,1H),3.60-3.77(m,2H),2.89( q,J=7.31Hz,1H),2.55(s,3H),1.71-1.90(m,4H),1.47-1.62(m,2H),0.92(t,J=7.13Hz,3H).

[0712] Example 45

[0713] (1R,2S)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopropane-1-carboxylic acid

[0714]

[0715] 0.050 mL of 2N NaOH (0.100 mmol) was added to a stirred solution of (1R,2S)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopentane-1-carboxylic acid ethyl ester (17.0 mg, 0.030 mmol) (intermediate 68) in 2 mL of MeOH. The volatiles were removed under reduced pressure after 64 h. Purification was performed by chromatography (Biotage Isolera, 12 g C18 column, eluting with a gradient of 0 to 25% B in solution A for 30 CV; A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH) to give (1R,2S)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamyl)cyclopropane-1-carboxylic acid as a grayish-white powder (11.5 mg, 0.022 mmol, 71.2% yield).

[0716] LCMS (Method 5): 0.72 min, 559.4 [M+H]+

[0717] 1 H NMR(400MHz,DMSO-d6)δppm 9.06-9.15(m,1H),8.73(d,J=7.89Hz,1H),8.36-8.46(m,1H),8.22-8.29(m,1H),7.78-7.91(m,2H),7.64-7.72(m,1H),7.43-7.54(m,2H) ,7.29-7.38(m,2H),5.00(d,J=5.48Hz,2H),4.70-4.78(m,2H),4.27(t,J=7.13Hz,1H),3.45-3.65(m,1H),2.55(s,3H),1.35-1.97(m,6H).

[0718] Example 46

[0719] (1S,2R)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopentane-1-carboxylic acid ethyl ester

[0720]

[0721] PyAOP (82 mg, 0.157 mmol) was added to a mixture of 2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetic acid (55 mg, 0.131 mmol) (intermediate 67a), ethyl (1S,2R)-2-aminocyclopentane-1-carboxylate (25 μL, 0.131 mmol), and DIPEA (68.5 μL, 0.393 mmol) in THF (3 mL). Stirring was continued for 1 h at room temperature. Formic acid (29.7 μL, 0.787 mmol) was then added, and volatiles were removed under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 30 g C18 column, eluting with a gradient of 0 to 30% B in solution A for 30 CV; A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH) to give (1S,2R)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamyl)cyclopentane-1-carboxylic acid ethyl ester as a grayish-white powder (27.5 mg, 0.049 mmol, 37.5% yield).

[0722] LCMS (Method 5): 0.72 min, 559.4 [M+H]+

[0723] 1 H NMR(400MHz,DMSO-d6)δppm 9.11(t,J=5.81Hz,1H),8.48(d,J=8.55Hz,1H),8.41(s,1H),8.26(d,J=1.53Hz,1H),7.84-7 .91(m,2H),7.72(d,J=1.53Hz,1H),7.49-7.53(m,1H),7.44-7.49(m,1H),7.34(t,J=8.88Hz, 2H),5.01(d,J=5.70Hz,2H),4.70-4.79(m,2H),4.36-4.43(m,1H),3.60-3.77(m,2H),2.89( q,J=7.31Hz,1H),2.55(s,3H),1.71-1.90(m,4H),1.47-1.62(m,2H),0.92(t,J=7.13Hz,3H).

[0724] Intermediate 69

[0725] (R)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidine-1,4-dicarboxylic acid 1-(tert-butyl)4-ethyl ester

[0726]

[0727] Cesium carbonate (152 mg, 0.466 mmol) was added to a stirred mixture of 1-(tert-butyl)-4-ethyl 4-(iodomethyl)piperidin-1,4-dicarboxylic acid (102 mg, 0.256 mmol) and (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazoline-8-ol (100 mg, 0.233 mmol) (intermediate 10) in DMF (2 mL). Stirring was continued at 100 °C for 5 h. The reaction mixture was diluted with AcOEt and washed with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purified by chromatography, (R)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidine-1,4-dicarboxylic acid 1-(tert-butyl)4-ethyl ester (39.9 mg, 0.057 mmol, 24.52% yield) was obtained.

[0728] LCMS (Method 5): 1.07 min, 698.8 m / z [M+H]+

[0729] Intermediate 70

[0730] (R)-1-(tert-butoxycarbonyl)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidin-4-carboxylic acid

[0731]

[0732] A solution of lithium hydroxide (140 mg, 5.85 mmol) in water (1 mL) was added to a solution of (R)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidin-1,4-dicarboxylic acid 1-(tert-butyl)4-ethyl ester (39.9 mg, 0.057 mmol) in THF (3 mL). Stirring was continued for 16 h at room temperature. Formic acid (300 μl, 7.95 mmol) was added, and volatiles were removed under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 30 g C18 column, gradient elution of solution A from 0 to 55% B, A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH, 15 CV) to give (R)-1-(tert-butoxycarbonyl)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidin-4-carboxylic acid as a grayish-white powder (17.9 mg, 0.027 mmol, 46.7% yield).

[0733] LCMS (Method 5): 0.96 min, 670.8 m / z [M+H]+,

[0734] 1 H NMR(400MHz,DMSO-d6)δppm 11.91-13.22(bs,1H),9.12(s,2H),8.56(br d,J=6.80Hz,1H),8.38(s,1H),8.17(s,1H),7.90(dd,J=8.66,5.59Hz,2H),7.53(s,1H),7.34(t,J=8.88Hz,2H),5.63(br t,J=6.91Hz,1H),4.28(s,2H),3.66(br d,J=13.59Hz,2H),2.94-3.20(m,2H),2.01(br d,J=13.81Hz,2H),1.69(d,J=7.02Hz,3H),1.57-1.66(m,2H),1.36(s,9H).

[0735] Example 47

[0736] (R)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidine-4-carboxylate salt

[0737]

[0738] 37% HCl (0.5 mL, 6.00 mmol) was added to a mixture of (R)-1-(tert-butoxycarbonyl)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidin-4-carboxylic acid (12.3 mg, 0.018 mmol) (intermediate 65) in 1 M HCl in AcOEt solution (2 mL, 2.000 mmol). Stirring was continued for 48 h at room temperature. Volatile substances were removed under reduced pressure. Purification was performed by RP chromatography (Biotage Isolera, 12 g C18 column, eluting gradient of 0 to 25% B in solution A, A: water / acetonitrile 95:5 + 0.1% HCl, B: acetonitrile:water 95:5 + 0.1% HCl, 15 CV) to give (R)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidine-4-carboxylate (6.1 mg, 10.05 μmol, 54.8% yield).

[0739] LCMS (Method 5): 0.59 min, 570.8 m / z [M+H]+

[0740] 1 H NMR(400MHz,DMSO-d6)δppm 13.9(br s,0.5H),13.1(br s,1H),10.7(br s,0.5H),9.19(br s,2H),9.05-8.30(m,4H),8.10-7.70(m,3H),7.39(t,J=8.66Hz,2H),6.00-5.66(m,1H),4 .56-4.30(m,2H),3.33(m,2H),3.01(m,2H),2.36-2.08(m,4H),1.78(brd,J=5.26Hz,3H).

[0741] Example 48

[0742] (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclohexane-1-carboxylic acid

[0743]

[0744] Intermediate 71

[0745] (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclohexane-1-carboxylic acid methyl ester

[0746]

[0747] Methyl 1-(bromomethyl)cyclohexane-1-carboxylate (90 mg, 0.384 mmol) was added to a stirred mixture of (R)-6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazoline-8-ol (150 mg, 0.349 mmol) (intermediate 10), sodium iodide (155 mg, 1.034 mmol), and cesium carbonate (240 mg, 0.737 mmol) in DMF (3 mL). Stirring was continued at 110 °C for 16 h, and then the reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc and washed with a saturated aqueous solution of ammonium chloride, followed by washing with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 28 g NH column, eluted with dichloromethane for 15 CV) to give (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclohexane-1-carboxylate as a pale yellow powder (50.9 mg, 0.087 mmol, 24.97% yield).

[0748] LCMS (Method 5): 1.02 min, m / z 583.9 [M+H]+

[0749] Preparation of (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclohexane-1-carboxylic acid (Example 48)

[0750]

[0751] A solution of lithium hydroxide (40 mg, 1.670 mmol) in water (1 mL) was added to a solution of (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclohexane-1-carboxylate (50.9 mg, 0.087 mmol) in THF (3 mL). Stirring was continued at 70 °C for 48 h. The reaction mixture was diluted with acetonitrile and volatiles were removed under reduced pressure. Purification was performed by chromatography (Biotage Isolera, 30 g C18 column, gradient elution of 0 to 20% B in solution A, A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 + 0.1% HCOOH, 15 CV) to give (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid as a pale beige powder (44.1 mg, 0.077 mmol, 89% yield).

[0752] LCMS (Method 5): 0.98 min, 570.2 m / z [M+H]+

[0753] 1 ¹H NMR (400MHz, DMSO-d6) δppm 12.16–12.43 (bs, 1H), 9.12 (s, 2H), 8.56 (br s, 1H), 8.39 (s, 1H), 8.16 (s, 1H), 7.90 (dd, J = 8.77, 5.48Hz, 2H), 7.52 (s, 1H), 7.34 (t, J = 8.77Hz, 2H), 5.63 (quintet, J = 6.96Hz, 1H), 4.23 (s, 2H), 2.00 (br dd,J=11.51,4.49Hz,1H),1.95-2.06(m,2H),1.69(d,J=7.23Hz,3H),1.38-1.57(m,6H),1.11-1.38(m,2H).

[0754] Intermediate 72

[0755] 2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)acetic acid dihydrochloride

[0756]

[0757] Step 1: Preparation of tert-butyl 2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)acetate

[0758]

[0759] 2-Bromoacetic acid tert-butyl ester (247 μL, 1.669 mmol) was added to a stirred mixture of 4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazoline-8-ol (500 mg, 1.391 mmol) (intermediate 57) and potassium carbonate (456 mg, 3.30 mmol) in DMF / THF 2:1 (9 mL). Stirring was continued for 16 h at room temperature. The reaction was quenched by adding formic acid (300 μL, 7.95 mmol) and volatiles were removed under reduced pressure. Purification was performed by RP chromatography (Biotage Isolera, 60 g C18 column, eluting with a gradient of 0 to 30% B in solution A; A: water / acetonitrile 95:5 + 0.1% HCOOH, B: acetonitrile:water 95:5 0.1% HCOOH) to give 2-((4-((((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)tert-butyl acetate (451 mg, 0.952 mmol, 68.5% yield) as an orange waxy substance.

[0760] LCMS (Method 5): 0.66 min, 473.8 [M+H]+

[0761] Step 2: Preparation of 2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)acetic acid dihydrochloride

[0762]

[0763] 2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazoline-8-yl)oxy)tert-butyl acetate was stirred in 4N HCl / 1,4-dioxane (20 ml, 80 mmol) at room temperature for 16 h. The volatiles were removed under reduced pressure to give 2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazoline-8-yl)oxy)acetic acid dihydrochloride (552 mg, 1.126 mmol, 81% yield) as a pale yellow powder.

[0764] LCMS (Method 5): 0.45 min, 418.0 [M+H]+,

[0765] 1H NMR(400MHz,DMSO-d6)δppm 11.20(br t,J=5.48Hz,1H),9.18(s,1H),8.88(s,2H),8.80(s,1H),8.41(s,1H),7.77(d,J= 8.55Hz,1H),7.65(d,J=8.55Hz,1H),5.16-5.28(m,4H),2.63(s,3H),2.38(s,3H)

[0766] Example 49

[0767] (2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)acetyl)(phenylsulfonyl)amide ammonium

[0768]

[0769] EDCI (58.6 mg, 0.306 mmol) was added to a stirred solution of 2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)acetic acid dihydrochloride (100 mg, 0.204 mmol) (intermediate 72), benzenesulfonamide (48.1 mg, 0.306 mmol), DMAP (100 mg, 0.816 mmol), and DIPEA (0.355 mL, 2.039 mmol) in DMF (2 mL). Stirring was continued for 16 h at room temperature. The reaction was quenched by adding formic acid (0.115 mL, 3.06 mmol), and the volatiles were removed under reduced pressure. Purification was performed by RP chromatography (Biotage Isolera, 12 g C18 column, eluting with a gradient of 0 to 25% B in solution A; A: water / MeOH 95:5 + 0.1% concentrated ammonia, B: MeOH / water 95:5 + 0.1% concentrated ammonia) to give (2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)acetyl)(phenylsulfonyl)amide ammonium (34.8 mg, 0.061 mmol, 29.7% yield) as a white powder.

[0770] LCMS (Method 5): 0.64 min, 557.1 [M+H]+,

[0771] 1H NMR(400MHz,DMSO-d6)δppm 9.34(br s,1H),8.84(s,1H),8.80(s,2H),8.39(s,1H),8.03(s,1H),7.72(d,J=7.67Hz,2H),7.40-7.50(m,2H),7.24-7.34(m,1H),7.18(br t,J=7.45Hz,4H),4.98(br d,J=5.26Hz,2H),4.60(s,2H),2.55(s,3H),2.35(s,3H)

[0772] Intermediate 73

[0773] 2-((6-(4-fluorophenyl)-4-(((1-methylpiperidin-4-yl)methyl)amino)quinazolin-8-yl)oxy)acetic acid hydrochloride

[0774]

[0775] Step 1: Preparation of tert-butyl (6-(4-fluorophenyl)-8-hydroxyquinazoline-4-yl)((1-methylpiperidin-4-yl)methyl)carbamate

[0776]

[0777] A solution of di-tert-butyl dicarbonate (1.641 mL, 7.14 mmol) in THF (10 mL) was added to a stirred solution of 6-(4-fluorophenyl)-4-(((1-methylpiperidin-4-yl)methyl)amino)quinazoline-8-ol (1.19 g, 3.25 mmol) (intermediate 5) and DIPEA (1.244 mL, 7.14 mmol) in THF (20 mL). Then, 4-dimethylaminopyridine (0.079 g, 0.649 mmol) was added and stirring continued for 16 h at room temperature. LCMS showed complete conversion to (8-((tert-butoxycarbonyl)oxy)-6-(4-fluorophenyl)quinazoline-4-yl)((1-methylpiperidin-4-yl)methyl)carbamate tert-butyl. Volatiles were removed under reduced pressure, and the residue was partitioned between EtOAc / THF 1:1 and a saturated aqueous solution of ammonium chloride. The layers were separated, and the organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was redissolved in dichloromethane (20 mL) and treated with a 2.0 M dimethylamine THF solution (4 mL). Stirring was continued at room temperature for 4 h, followed by removal of volatiles under reduced pressure. Purification was performed by column chromatography (Biotage Isolera, 55 g NH column, eluting with a gradient of 0 to 30% EtOH in dichloromethane) to give tert-butyl (6-(4-fluorophenyl)-8-hydroxyquinazoline-4-yl)((1-methylpiperidin-4-yl)methyl)carbamate (398 mg, 0.853 mmol, 26.3% yield) as an orange powder.

[0778] LCMS (Method 5): 1.32 min, 467.4 [M+H]+.

[0779] Step 2: Preparation of 2-((6-(4-fluorophenyl)-4-(((1-methylpiperidin-4-yl)methyl)amino)quinazolin-8-yl)oxy)acetic acid hydrochloride (intermediate 73)

[0780]

[0781] 2-Bromoacetic acid tert-butyl ester (0.075 mL, 0.509 mmol) was added to a stirred suspension of potassium carbonate (147 mg, 1.061 mmol) and (6-(4-fluorophenyl)-8-hydroxyquinazoline-4-yl)((1-methylpiperidin-4-yl)methyl)carbamate tert-butyl ester (198 mg, 0.424 mmol) in DMF (2 mL). Stirring was continued at room temperature for 16 h. The reaction mixture was diluted with EtOAc and washed with brine (3×). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification was performed by column chromatography (Biotage Isolera, 28 g NH column, eluted with a gradient of 0 to 20% AcOEt in dichloromethane) to give intermediate 2-((4-((tert-butoxycarbonyl)((1-methylpiperidin-4-yl)methyl)amino)-6-(4-fluorophenyl)quinazoline-8-yl)oxy)acetic acid tert-butyl ester. The substance was dissolved in 1,4-dioxane (3 mL) at room temperature and then treated with 4N HCl at room temperature for 18 h. The volatiles were removed under reduced pressure to give 2-((6-(4-fluorophenyl)-4-(((1-methylpiperidin-4-yl)methyl)amino)quinazolin-8-yl)oxy)acetic acid hydrochloride as a pale yellow powder (88.1 mg, 0.191 mmol, 45.0% yield).

[0782] LCMS (Method 5): 0.33 min, 425.2 [M+H]+

[0783] 1 H NMR (400MHz, DMSO-d6) δppm 13.95-14.23(bs,1H),10.65-10.55(bs,1H),10.11-10.18(m,1H),8.72(s,1H),8.53(s,1H),7.95(br dd,J=8.33,5.48Hz,2H),7.87(s,1H),7.38(t,J=8.77Hz,2H),5.19(s,2H),3.60-3.50(m,2H),3.17-3.34(br s,3H),2.74-2.90(m,2H),2.67(s,3H),2.50-2.53(m,1H),1.97-2.05(m,1H),1.90(br d,J=13.37Hz,2H),1.40-1.61(m,2H)

[0784] Intermediate 74

[0785] Methyl methanesulfonate (3-methyl-1,2,4-oxadiazol-5-yl)

[0786]

[0787] A solution of (3-methyl-1,2,4-oxadiazol-5-yl)methanol (300 mg, 2.63 mmol) and triethylamine (1.1 mL, 7.89 mmol) in DCM (6 mL) was stirred at 0 °C for 5 min. Methanesulfonyl chloride (0.41 mL, 5.26 mmol) was added, and the reaction mixture was stirred at 0 °C for 15 min. The reaction was then heated to room temperature and stirred for 16 h. The reaction was partitioned between DCM and water, and the two phases were separated. The aqueous phase was extracted with DCM, and the combined organic phases were passed through phase separation paper. The solvent was removed under vacuum to give the title compound (290 mg, 57% yield) as an orange oil.

[0788] 1H NMR (400MHz, CDCl3): δ4.66 (s, 2H), 3.49 (s, 3H), 2.43 (s, 3H).

[0789] Intermediate 75

[0790] 6-(4-Fluorophenyl)-8-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine

[0791]

[0792] Methyl 3-methyl-1,2,4-oxadiazol-5-yl methanesulfonate (176 mg, 0.46 mmol), 6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-ol (150 mg, 0.23 mmol), and cesium carbonate (223 mg, 0.69 mmol) were dissolved in DMF (4 mL). The reaction mixture was heated at 55 °C for 16 hours. The reaction mixture was cooled to room temperature and then partitioned between DCM and water. The two phases were separated, and the aqueous phase was extracted with DCM (×2). The combined organic phases were passed through phase separation paper and concentrated under vacuum. Purification by preparative HPLC yielded the title compound (78.1 mg, 75%) as a grayish-white solid.

[0793] 1H NMR (400MHz, DMSO): δ9.13(t,J=5.9Hz,1H),8.45(s,1H),8.30(d,J=1.5Hz,1H),7.95-7.90(m,2H),7.75(d,J=1.6 Hz,1H),7.59-7.49(m,2H),7.43-7.38(m,2H),5.80(s,2H),5.04(d,J=5.9Hz,2H),2.61-2.60(m,3H),2.39(s,3H). LCMS (Method 3): [MH+ =458, at 4.29 min.

[0794] The following compounds were prepared by adapting the above procedure to the substrates reported in the table.

[0795]

[0796]

[0797]

[0798]

[0799]

[0800]

[0801]

[0802]

[0803] The pharmacological activities of the compounds of this invention.

[0804] In vitro electrophysiological assays of P2X3

[0805] Cells expressing the P2X3 receptor were grown according to standard practice and maintained at 37°C in a humidified CO2 atmosphere of 5%. Two days prior to the assay date, cells were seeded into T175 flasks and detached from the flasks using a TrypLE when they reached 80–90% confluence. The detached cells were then seeded at 3 × 10⁻⁶ cells / day. 6Cells were resuspended at a density of 10 cells / ml in serum-free medium and loaded onto the Sophon Qube automated patch-clamp system. Extracellular assay buffer contained 145 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose, pH 7.4. Intracellular assay solution contained 140 mM CsF, 10 mM NaCl, 10 mM EGTA, and 10 mM HEPES, pH 7.2. Agonist stock solutions were prepared in H2O and diluted in bath solution before use. All antagonists were prepared as 10 mM stock solutions in DMSO and diluted in bath solution before use. All experiments were performed at room temperature in a whole-cell patch-clamp configuration, with 384 individual cells voltage-clamped at -60 mV on the Sophon Qube instrument. Two baseline responses were established using α,β-MeATP (800 nM), followed by washing away the agonist with extracellular assay buffer containing 0.5 U / ml adenosine triphosphate bisphosphatase. After the second agonist administration, the antagonist was incubated for 10 minutes in the absence of α,β-MeATP. Following antagonist pre-incubation, 800 nM α,β-MeATP and the antagonist were co-administered to determine the inhibitory effect of the antagonist. To assess the antagonist concentration for single-cell evaluation, different concentrations of the antagonist were administered to other cells on the 384 recording substrate. The control P2X3 current amplitude was taken from the peak current amplitude of the second agonist response prior to antagonist pre-incubation. The inhibitory effect at each antagonist concentration was calculated using the peak P2X3 current amplitude in the presence of the antagonist according to the following equation:

[0806] Percentage inhibition of P2X3 = (Peak amplitude of P2X3 control - Peak amplitude of P2X3 antagonist) / Peak amplitude of P2X3 control * 100

[0807] Concentration-response curves were constructed using ten different concentrations of the antagonist, each tested on at least two separate cells. The antagonist concentration (IC50) that inhibited 50% of the P2X3 current was determined by fitting the data with the following equation. 50 ):

[0808] Y=a+[(ba) / (1+10^((log cx)d)]

[0809] Where 'a' represents the minimum reaction, 'b' represents the maximum reaction, and 'c' represents the IC50 value. 50 And 'd' is the slope of Hill.

[0810] Results for each compound are provided in Table 2 below and are expressed as a range of activity.

[0811] Table 2

[0812]

[0813]

[0814]

[0815] The compounds are classified according to their efficacy in inhibiting P2X3 activity, based on the following classification criteria:

[0816] +++: pIC 50 h P2X3>6.5

[0817] ++: 6.5 <pIC 50 h P2X3>5.5

[0818] +: 5.5 <pIC 50 h P2X3>4.5

[0819] P2X 2 / 3 In vitro electrophysiological assays

[0820] For P2X 2 / 3 The receptor was also tested, along with representative compounds of the present invention.

[0821] For P2X 2 / 3 The assay was performed using the same assay protocol as the P2X3 assay, with two modifications: 1) 10 μM ATP was used as the agonist; and 2) the average current amplitude was measured seven seconds after the agonist was applied.

[0822] The results in Table 3 indicate that the representative compound of the present invention is a selective P2X3 antagonist.

[0823] Table 3

[0824]

[0825]

[0826] The following classification criteria are used to classify compounds based on their properties of P2X3 or P2X. 2 / 3 The efficacy of the same type of inhibitory activity is used to classify compounds:

[0827] +++: pIC 50 h P2X3 or h P2X 2 / 3 >6.5

[0828] ++: 6.5 <pIC 50 h P2X3 or h P2X 2 / 3 >5.5

[0829] +: 5.5 <pIC50 h P2X3 or h P2X 2 / 3 >4.5

[0830] Comparative Example A

[0831] N-(6-(4-fluorophenyl)chroman-4-yl)-2-(trifluoromethyl)pyrimidin-5-carboxamide

[0832]

[0833] The activity of Comparative Example A has been tested in an in vitro assay as described above for determining the activity against the P2X3 receptor.

[0834] Unlike the compounds of formula (I) of the present invention, Comparative Example A does not show adequate inhibitory activity against P2X3, in fact, at pIC 50 The indicated activity against receptor P2X3 is <4.5.

[0835] The above results demonstrate that the combination of the aminoquinazoline skeleton with appropriate substituents, particularly those at the R2 position, unexpectedly produces a series of compounds active against the receptor P2X3.

Claims

1. A compound selected from the group consisting of: 8-(2,2-Difluoroethoxy)-6-(4-fluorophenyl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine, (R)-8-(2,2-difluoroethoxy)-6-(4-fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazolin-4-amine, 8-(2,2-Difluoroethoxy)-6-(5-fluoropyridin-2-yl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine, (R)-8-(2,2-difluoroethoxy)-6-(5-fluoropyridin-2-yl)-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine, 8-(2,2-difluoroethoxy)-6-(5-fluoro-2-pyridyl)-N-[1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl]quinazolin-4-amine, 8-(2,2-Difluoroethoxy)-N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)quinazolin-4-amine, 8-(2,2-Difluoroethoxy)-N-[(6-methylpyridazin-3-yl)methyl]-6-(5-methylpyrimidin-2-yl)quinazolin-4-amine, (R)-8-((3,3-difluoropyrrolidone-1-yl)sulfonyl)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)quinazolin-4-amine, (R)-8-((3,3-difluoropyrrolidone-1-yl)sulfonyl)-6-(4-fluorophenyl)-N-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine, 8-((3,3-difluoropyrrolidone-1-yl)sulfonyl)-6-(4-fluorophenyl)-N-(1-(5-methyl-1,3,4-thiadiazol-2-yl)ethyl)quinazolin-4-amine, (R)-1-((6-(4-fluorophenyl)-4-((1-(6-methylpyridazin-3-yl)ethyl)amino)quinazolin-8-yl)sulfonyl)piperidin-4-ol, (R)-1-((6-(4-fluorophenyl)-4-((1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)amino)quinazolin-8-yl)sulfonyl)piperidin-4-ol, (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(methylthio)quinazolin-4-amine, 6-(4-fluorophenyl)-N-((R)-1-(6-methylpyridazin-3-yl)ethyl)-8-(methylsulfinyl)quinazolin-4-amine, (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)-8-(oxetane-3-ylthio)quinazolin-4-amine, 6-(4-fluorophenyl)-N-((R)-1-(6-methylpyridazin-3-yl)ethyl)-8-(oxetane-3-ylsulfinyl)quinazolin-4-amine, (1-((S)-3-((6-(4-fluorophenyl)-4-(((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)pyrrolid-1-yl)acet-1-one, (1-((R)-3-((6-(4-fluorophenyl)-4-(((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)pyrrolid-1-yl)ethyl-1-one, N-((1S,4S)-4-((6-(4-fluorophenyl)-4-(((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)cyclohexyl)acetamide, 6-(4-fluorophenyl)-8-((1-(2,2,2-trifluoroethyl)pyrrolidine-3-yl)oxy)-N-((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazoline-4-amine, 3-((6-(4-fluorophenyl)-4-(((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)pyrrolidine-2-one, (R)-1-(4-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)piperidin-1-yl)ethyl-1-one, (R)-6-(4-fluorophenyl)-8-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)oxy)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinazoline-4-amine, (R)-3-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)oxetane-3-ol, (R)-5-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)isoxazo-3-ol, (R)-2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)-N-(phenylsulfonyl)acetamide, (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid, 1-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)methyl cyclopropane-1-carboxylate, (R)-1-(2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetamido)methyl cyclopropane-1-carboxylate, (R)-1-(2-((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopropane-1-carboxylic acid, (1R,2S)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopropane-1-carboxylic acid, (1S,2R)-2-(2-((6-(4-fluorophenyl)-4-(((6-methylpyridazin-3-yl)methyl)amino)quinazolin-8-yl)oxy)acetamido)cyclopentane-1-carboxylic acid ethyl ester, (R)-4-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)piperidine-4-carboxylate salt, (R)-1-(((6-(4-fluorophenyl)-4-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)amino)quinazolin-8-yl)oxy)methyl)cyclohexane-1-carboxylic acid, (2-((4-(((6-methylpyridazin-3-yl)methyl)amino)-6-(5-methylpyrimidin-2-yl)quinazolin-8-yl)oxy)acetyl)(phenylsulfonyl)amide ammonium, 6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-[[1-(trifluoromethyl)cyclopropyl]methoxy]quinazolin-4-amine, 3-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyaziridine-1-carboxylic acid tert-butyl ester, 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyacetonitrile, 2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxy-N-methoxy-N-methylacetamide, 2-[2-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxyethoxy]ethanol, 6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]-8-(oxazol-2-ylmethoxy)quinazolin-4-amine, 6-(4-fluorophenyl)-8-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine, 8-[(3-ethyl-1,2,4-oxadiazol-5-yl)methoxy]-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine, 8-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methoxy]-6-(4-fluorophenyl)-N-[(6-methylpyridazin-3-yl)methyl]quinazolin-4-amine, 8-((5-cyclopropyl-1,3,4-oxadiazol-2-yl)methoxy)-6-(4-fluorophenyl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine, 4-[[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxymethyl]piperidine-1-carboxylic acid methyl ester, 4-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxypiperidine-1-carboxylic acid methyl ester, 3-[[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxymethyl]piperidine-1-carboxylic acid methyl ester, 3-[[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxymethyl]pyrrolidine-1-carboxylic acid methyl ester, 3-[6-(4-fluorophenyl)-4-[(6-methylpyridazin-3-yl)methylamino]quinazolin-8-yl]oxypyrrolidine-1-carboxylic acid methyl ester, Or its pharmaceutically acceptable salt.

2. A pharmaceutical composition comprising, alone or in combination with one or more pharmaceutically acceptable carriers or excipients, a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition according to claim 2, for oral administration.

4. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 2 or 3 in the preparation of a medicament for treating a disease involving a P2X3 receptor.

5. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 2 or 3 in the preparation of a medicament for the prevention and / or treatment of respiratory diseases, including cough, asthma, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease.

6. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 2 or 3 in the preparation of a medicament for the prevention and / or treatment of chronic cough.

7. The use according to claim 5, wherein the cough is selected from subacute or chronic cough, refractory cough, postviral cough, and iatrogenic cough.

8. The use according to claim 6 or 7, wherein the chronic cough is idiopathic chronic cough.

9. Use of the compound of claim 1 or the pharmaceutical composition of claim 2 or 3 in the preparation of a medicament for the prevention and / or treatment of cough associated with a respiratory disease, wherein the respiratory disease is selected from chronic obstructive pulmonary disease, asthma, and bronchospasm.

Citation Information

Patent Citations

  • Tetrazole-substituted arylamides

    WO2008000645A1

  • Pyrid-2-YL fused heterocyclic compounds, and compositions and uses thereof

    WO2008123963A1

  • 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof

    WO2008130481A1

  • Amide compounds, compositions and uses thereof

    WO2009110985A2

  • Amide compounds, compositions and uses thereof

    WO2010033168A2